Improved methods in lentiviral manufacture for producing CAR-T cell drug products

By adjusting the lentiviral vector ratio and transfection time, the problem of insufficient infectivity titer in lentiviral preparation in existing technologies has been solved, achieving efficient and safe CAR-T cell preparation, reducing costs and improving preparation efficiency.

CN121986171APending Publication Date: 2026-05-05JANSSEN BIOTECH INC
View PDF 13 Cites 0 Cited by

Patent Information

Application Number
CN202480064314.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-10-05
Filing Date
2024-10-04
Publication Date
2026-05-05

AI Technical Summary

Technical Problem

Existing lentiviral packaging systems suffer from low live virus concentrations and insufficient infectious titers when preparing CAR-T cells, leading to the need for increased virus dosage, increased costs, and safety concerns. Furthermore, the carrier ratio of four-carrier packaging systems has not been determined to ensure high infectious titers and good safety.

Method used

By using specific vector ratios (such as 2:1:1:1, 11:3:1:5, or 12:2:1:5), the first, second, third, and fourth vectors encoding CAR polynucleotides are combined with the transfection medium. After transfection into host cells, the cells are cultured and harvested at appropriate times to increase the infectivity titer of the lentivirus.

Benefits of technology

It improved the infectivity titer of lentiviruses, reduced costs, and enhanced the efficiency and safety of CAR-T cell preparation, thus meeting the needs of CAR-T therapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121986171A_ABST
    Figure CN121986171A_ABST
Patent Text Reader

Abstract

The present application relates to improvements in lentiviral manufacturing for the production of CAR-T cell drug products wherein the manufacturing method comprises a change in time between transfection and harvest of the host cell, and a new vector ratio for transfection. Presented herein are methods of making lentiviruses at various vector ratios and the time between host cell transfection and harvest, as well as transfection compositions comprising various vector ratios.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Cross-references to related applications

[0002] This application claims the benefit of U.S. Provisional Application No. 63 / 588,148, filed on October 5, 2023, which is incorporated herein by reference in its entirety.

[0003] sequence list

[0004] This application includes a sequence list that has been electronically submitted in XML format, and is incorporated herein by reference in its entirety. The XML copy was created on August 28, 2024, named "258199091502(JBI6821WOPCT1)SequenceListing.xml", and has a size of 31,678 bytes. Technical Field

[0005] This application relates to improvements in the manufacture of lentiviruses for CAR-T cell preparation. Background Technology

[0006] Chimeric antigen receptor T-cell (CAR-T) therapy utilizes isolated T cells that have been genetically modified to enhance their specificity for specific tumor-associated antigens. These T cells are typically autologous T cells, isolated from a patient who will receive T-cell therapy. These isolated T cells are then genetically modified using lentiviruses to express chimeric antigen receptors (CARs). T cells expressing chimeric antigen receptors (CAR-T cells) can induce tumor immune responses.

[0007] Lentivirals prepared using currently available vector packaging systems for T-cell genetic modification exhibit low concentrations of live virus and low infectious titers. To achieve optimal T-cell transduction, higher doses of lentivirus are required, but this incurs drawbacks such as increased cost, excessive residue, and poor safety profile. While four-vector packaging systems have been used in existing technologies to replace three-vector systems, the appropriate ratio of vectors to provide higher infectious titers while ensuring good safety has not yet been determined. Therefore, there remains a pressing need to screen for suitable ratios of the four vectors used to package lentiviruses for the genetic modification of isolated T cells for CAR-T therapy. Summary of the Invention

[0008] This article provides a method for preparing lentiviruses for manufacturing chimeric antigen receptor (CAR) T-cell (CAR-T) drug products. The method includes: transfecting host cells with a transfection composition comprising: a first vector, a second vector, a third vector, and a fourth vector encoding a polynucleotide of CAR; and a transfection medium; wherein the ratio of the first vector to the second vector to the third vector to the fourth vector is 2:1:1:1, 11:3:1:5, or 12:2:1:5; culturing the transfected host cells to proliferate; and harvesting the lentivirus, wherein the harvest occurs approximately 24 hours after transfection.

[0009] This article also provides a method for preparing lentiviruses for manufacturing chimeric antigen receptor (CAR) T-cell (CAR-T) drug products, the method comprising: transfecting host cells with a transfection composition comprising: a first vector, a second vector, a third vector, and a fourth vector encoding a polynucleotide of CAR; and a transfection medium; wherein the ratio of the first vector to the second vector to the third vector to the fourth vector is 11:3:1:5 or 12:2:1:5; culturing the transfected host cells to proliferate; and harvesting the lentivirus, wherein the harvest occurs less than or equal to about 48 hours post-transfection.

[0010] In some embodiments, the ratio is 2:1:1:1. In some embodiments, the ratio is 11:3:1:5. In some embodiments, the ratio is 12:2:1:5. In some embodiments, harvest occurs approximately 24 hours after transfection. In some embodiments, the first, second, third, and fourth vectors comprise lentiviral vectors. In some embodiments, the ratio is 2:1:1:1, and harvest occurs approximately 24 hours after transfection. In some embodiments, the ratio is 11:3:1:5, and harvest occurs approximately 24 hours after transfection. In some embodiments, the ratio is 12:2:1:5, and harvest occurs approximately 24 hours after transfection.

[0011] In one embodiment, the second vector contains a polynucleotide encoding a lentiviral envelope protein. In some embodiments, the lentiviral envelope protein is vesicular stomatitis virus G (VSVG). In some embodiments, the third vector contains polynucleotides encoding GAG and POL. In some embodiments, the fourth vector contains a polynucleotide encoding REV.

[0012] In some embodiments, the culture is carried out in a bioreactor. In some embodiments, the bioreactor is a 2L, 10L, or 50L bioreactor. In some embodiments, the host cell is HEK 293 cell. In some embodiments, the host cell is HEK 293F cell. In some embodiments, the CAR immunospecifically targets B cell maturation antigen (BCMA).

[0013] A method for preparing a lentivirus for manufacturing a BCMA CAR-T drug product is provided, the method comprising: transfecting host cells with a transfection composition comprising: a first vector, a second vector, a third vector, and a fourth vector containing a polynucleotide encoding an immune-specific CAR targeting BCMA; and a transfection medium; wherein the ratio of the first vector to the second vector to the third vector to the fourth vector is 2:1:1:1, 11:3:1:5, or 12:2:1:5; culturing the transfected host cells to proliferate; and harvesting the lentivirus, wherein the harvest occurs approximately 24 hours after transfection.

[0014] This article also provides a method for preparing lentiviruses for manufacturing BCMA CAR-T drug products, the method comprising: transfecting host cells with a transfection composition comprising: a first vector, a second vector, a third vector, and a fourth vector containing a polynucleotide encoding an immune-specific CAR targeting BCMA; and a transfection medium; wherein the ratio of the first vector to the second vector to the third vector to the fourth vector is 11:3:1:5 or 12:2:1:5; culturing the transfected host cells to proliferate; and harvesting the lentivirus, wherein the harvest occurs less than or equal to about 48 hours post-transfection.

[0015] In some implementations, the ratio is 2:1:1:1. In some implementations, the ratio is 11:3:1:5. In some implementations, the ratio is 12:2:1:5. In some implementations, harvest occurs approximately 24 hours after transfection. In some implementations, the first, second, third, and fourth vectors comprise lentiviral vectors. In some implementations, harvest occurs approximately 24 hours after transfection. In some implementations, harvest occurs approximately 24 hours after transfection. In some implementations, the ratio is 12:2:1:5, and harvest occurs approximately 24 hours after transfection.

[0016] In some embodiments, the second vector contains a polynucleotide encoding a lentiviral envelope protein. In some embodiments, the lentiviral envelope protein is vesicular stomatitis virus G (VSVG). In some embodiments, the third vector contains polynucleotides encoding GAG and POL. In some embodiments, the fourth vector contains a polynucleotide encoding REV.

[0017] In some embodiments, the culture is carried out in a bioreactor. In some embodiments, the bioreactor is a 2L, 10L, or 50L bioreactor. In some embodiments, the host cell is HEK 293 cells. In some embodiments, the host cell is HEK 293F cells.

[0018] In some embodiments, the first vector contains SEQ ID NO: 1. In some embodiments, the second vector contains SEQ ID NO: 2. In some embodiments, the third vector contains SEQ ID NO: 3. In some embodiments, the fourth vector contains SEQ ID NO: 4. In some embodiments, the CAR-T drug product is ciltacabtagene autolucel (cilta-cel).

[0019] This article provides a transfection composition comprising: a first vector, a second vector, a third vector, and a fourth vector encoding a polynucleotide, and a transfection medium; wherein the ratio of the first vector to the second vector to the third vector to the fourth vector is 2:1:1:1, 11:3:1:5, or 12:2:1:5.

[0020] In some implementations, the ratio is 2:1:1:1. In some implementations, the ratio is 11:3:1:5. In some implementations, the ratio is 12:2:1:5.

[0021] In some embodiments, the second vector contains a polynucleotide encoding a lentiviral envelope protein. In some embodiments, the lentiviral envelope protein is vesicular stomatitis virus G (VSVG). In some embodiments, the third vector contains polynucleotides encoding GAG and POL. In some embodiments, the fourth vector contains a polynucleotide encoding REV.

[0022] In some embodiments, the CAR immunospecifically targets B cell maturation antigen (BCMA). In some embodiments, the first vector comprises SEQ ID NO: 1. In some embodiments, the second vector comprises SEQ ID NO: 2. In some embodiments, the third vector comprises SEQ ID NO: 3. In some embodiments, the fourth vector comprises SEQ ID NO: 4.

[0023] This document provides a method for manufacturing a BCMA CAR-T drug product, comprising: providing activated T cells from apheresis material from a subject suffering from multiple myeloma; contacting the T cells with a lentivirus prepared by any method disclosed herein or by using a transfection composition disclosed herein; culturing the transfected T cells to proliferate; and harvesting the CAR-T drug product. In some embodiments, the BCMA CAR-T drug product is cilta-cel. This document also provides a method for treating multiple myeloma, comprising administering a CAR-T drug product prepared by any method disclosed herein to a subject in need. Attached Figure Description

[0024] Figure 1 This is a flowchart illustrating the steps in the CAR T-cell lentivirus manufacturing process.

[0025] Figures 2A to 2D A diagram of the vectors used in the four-vector lentivirus manufacturing process is shown. Figure 2A The transfer vector containing the target gene (“GOI”) is depicted, here in CAR coding sequence. Figure 2B The envelope carrier (“MD2g”) that encodes VSVG is described. Figure 2C The first packaging carrier (“MDLg”) that encodes GAG and POL is described. Figure 2D The second packaging carrier (“RSV-REV”) coded REV is depicted.

[0026] Figure 3A and Figure 3B This is a graph showing the approximate proportions of each of the four vectors (GOI, MD2G, MDLg, and RSV-REV) involved in the creation of CAR T lentiviruses. Figure 3A The infectious titer according to the SUPT1 method is shown, and Figure 3B The infectious titer according to the AD TU Flow method is shown.

[0027] Figure 4A and Figure 4B This is a graph showing the approximate ratios of each of the four vectors (GOI, MD2G, MDLg, and RSV-REV) involved in the manufacturing process of CAR T lentivirus, with MDLg and RSV-REV vectors controlled at a fixed ratio. Figure 4A The infectious titer according to the SUPT1 method is shown, and Figure 4B The infectious titer according to the AD TU Flow method is shown.

[0028] Figure 5A and Figure 5BSUPT1 was described with a vector ratio of 2:1:1:1 (SOP), 11:3:1:5 (vector ratio 1), and 12:2:1:5 (vector ratio 2). Figure 5A ) and API P24 ( Figure 5B A single-valued graph of ).

[0029] Figures 6A to 6D The SUPT1 ( ) was described under production conditions of 24 hours, 36 hours, 48 ​​hours and 72 hours. Figure 6A P24 Figure 6B HCP ( Figure 6C ) and HCDNA ( Figure 6D Values ​​of )

[0030] Figures 7A to 7D The differences between four manufacturing conditions were described: 24-hour harvest time for a 2:1:1:1 carrier ratio (n=23), 24-hour harvest time for an 11:3:1:5 carrier ratio (n=26), 48-hour harvest time for a 2:1:1:1 carrier ratio (n=25), or 48-hour harvest time for an 11:3:1:5 carrier ratio (n=19). Figure 7A It is a graph showing the infectious titers between the groups, and Figures 7B to 7D This is a diagram of various impurities (infectious particles). Figure 7B Host cell DNA, Figure 7C Host cell proteins, Figure 7D ).

[0031] Figures 8A to 8D The upstream results were described for harvesting at 48 hours post-transfection (control) with a vector ratio of 2:1:1:1, at 24 hours post-transfection, and at 24 hours post-transfection with a vector ratio of 11:3:1:5. Figure 8A The IT flow is shown. Figure 8B The P24 level is shown. Figure 8C It shows the host cell protein levels, and Figure 8D The host cell DNA level was shown.

[0032] Figures 9A to 9G The downstream post-production processing and formulation analysis are described. Figure 9A The TU-flow titer is shown. Figure 9B The IT-PCR titer is shown. Figure 9C p24 level is shown. Figure 9D The P / I level is shown. Figure 9E It shows the host cell protein level, Figure 9F It showed the host cell DNA level, and Figure 9G The vector DNA level is shown.

[0033] Figures 10A to 10D The final drug product results were depicted for the following vector ratios: 48 hours post-transfection (control), 24 hours post-transfection (option 1), and 11:3:1:5 (option 2). Figure 10A The percentage of CAR plus T cells is shown. Figure 10B This demonstrates the vitality of the drug product. Figure 10C The copy number of the carrier is shown, and Figure 10D The efficacy of the drug product is demonstrated.

[0034] Figure 11 This is a flowchart depicting the complete end-to-end drug product manufacturing operation starting from a single sample, but the operation is divided into four separate but simultaneous transduction and amplification processes using lentiviruses manufactured under different conditions: 1) 50L bioreactor, 48 hours post-transfection incubation, 2:1:1:1 vector ratio control group (50L control); 2) 10L bioreactor, 48 hours post-transfection incubation, 2:1:1:1 vector ratio control group (10L control); 3) 10L bioreactor, 24 hours post-transfection incubation, 2:1:1:1 vector ratio experimental group (10L option 1); and 4) 10L bioreactor, 24 hours post-transfection incubation, 11:3:1:5 vector ratio experimental group (10L option 2).

[0035] Figures 12A to 12E The results of experiments using individual apheresis materials from different patients are described. Figure 12A The percentage of CAR T cells in the drug product is shown. Figure 12B This demonstrates the vitality of the drug product. Figure 12C This demonstrates carrier integration. Figure 12D The effects on various T-cell immune phenotypes were shown, and Figure 12E Cell growth is shown. In each figure, the aspirated material from the first patient is shown in the top figure, and the aspirated material from the second patient is shown in the bottom figure.

[0036] Figure 13 A flowchart illustrating a downstream purification process for harvested materials following upstream bioreactor operation is provided.

[0037] Figures 14A to 14DThe upstream results are depicted at a 50L scale with a 2:1:1:1 vector ratio at 48 hours post-transfection (control), a 2:1:1:1 vector ratio at 24 hours post-transfection, an 11:3:1:5 vector ratio at 24 hours post-transfection, a 2:1:1:1 vector ratio at 48 hours post-transfection (control), and at a 50L scale with a 2:1:1:1 vector ratio at 24 hours post-transfection. Figure 14A The IT flow is shown. Figure 14B The P24 level is shown. Figure 14C It shows the host cell protein levels, and Figure 14D The host cell DNA level was shown.

[0038] Figures 15A to 15G Downstream results of post-production processing and formulation analysis were described for 50L scale only with a 2:1:1:1 carrier ratio (control), 24 hours post-transfection harvest time with a 2:1:1:1 carrier ratio (option 1), 11:3:1:5 carrier ratio (option 2), 48 hours post-transfection harvest time with a 2:1:1:1 carrier ratio (control), and 24 hours post-transfection harvest time with a 2:1:1:1 carrier ratio (control) at 50L scale only. Figure 15A The TU-flow titer is shown. Figure 15B The IT-PCR titer is shown. Figure 15C p24 level is shown. Figure 15D The P / I level is shown. Figure 15E It shows the host cell protein level, Figure 15F It showed the host cell DNA level, and Figure 15G The vector DNA level is shown.

[0039] Figures 16A to 16D The final drug product results were depicted at a 50L scale only with a 2:1:1:1 vector ratio at 48 hours post-transfection (control), a 2:1:1:1 vector ratio at 24 hours post-transfection (option 1), an 11:3:1:5 vector ratio at 24 hours post-transfection (option 2), a 2:1:1:1 vector ratio at 48 hours post-transfection (control), and a 50L scale only with a 2:1:1:1 vector ratio at 24 hours post-transfection. Figure 16A The percentage of CAR plus T cells is shown. Figure 16B This demonstrates the vitality of the drug product. Figure 16C The copy number of the carrier is shown, and Figure 16D The efficacy of the drug product is demonstrated.

[0040] Figures 17A to 17D Describing the use of Figures 16A to 16D The results of the experiment were performed using the method shown, but the experiment was run twice with separate single-collection materials from different patients. Figure 17A The percentage of CAR T cells in the drug product is shown. Figure 17B This demonstrates the vitality of the drug product. Figure 17C This demonstrates carrier integration. Figure 17D The efficacy of the drug product is shown. In each figure, the apheresis material from the first patient is shown in the upper figure, and the apheresis material from the second patient is shown in the lower figure. Detailed Implementation

[0041] The techniques and procedures described or cited herein include those commonly known to those skilled in the art and / or commonly employed using conventional methods, such as those widely used as described in the following literature: Sambrook et al., Molecular Cloning: A Laboratory Manual (3rd edition, 2001); Current Protocols in Molecular Biology (edited by Ausubel et al., 2003).

[0042] Unless otherwise defined herein, the technical and scientific terms used in this specification have the meanings commonly understood by one of ordinary skill in the art. For the purposes of interpreting this specification, the following terminology will be applied, and where appropriate, terms used in the singular will also include the plural, and vice versa. In the event of any conflict between any description of the terms set forth herein and any document incorporated herein by reference, the description of the terms set forth below shall prevail.

[0043] To assist readers of this application, the specification has been divided into paragraphs or chapters. These divisions are not intended to separate the substance of one paragraph or chapter from the substance of another. Rather, this specification covers all possible combinations of chapters, paragraphs, and sentences.

[0044] As used in this article, unless the context clearly indicates otherwise, the indefinite articles “a,” “a kind,” and “the” should be understood to include plural references.

[0045] The term "about" or "approximately" includes a range of values ​​that are statistically significant. Such a range may be within the order of magnitude of a given value or range, preferably within 50%, more preferably within 20%, still more preferably within 10%, and even more preferably within 5%. The permissible variation covered by the term "about" or "approximately" depends on the system under study and can be readily understood by one of ordinary skill in the art.

[0046] A chimeric antigen receptor (CAR) is an artificially constructed hybrid protein or polypeptide containing an antigen-binding domain of an antibody (or antibody fragment) linked to a T cell signaling domain. CAR properties include their ability to specifically and reactivityly redirect T cells to selected targets in a non-MHC-restricted manner, thus utilizing the antigen-binding properties of monoclonal antibodies. Non-MHC-restricted antigen recognition confers the ability of CAR-expressing T cells to recognize antigens independently of antigen processing, thus bypassing major mechanisms of tumor escape. Furthermore, advantageously, when expressed in T cells, CARs do not dimerize with the α and β chains of the endogenous T cell receptor (TCR). CAR-expressing T cells are referred to herein as CAR T cells, CAR-T cells, or CAR-modified T cells, and these terms are used interchangeably herein. The cell can be genetically modified to stably express an antibody-binding domain on its surface, thereby conferring novel MHC-independent antigen specificity. A "BCMA CAR" refers to a CAR having an extracellular binding domain specific for BCMA.

[0047] As used herein, the terms “specific binding,” “specific recognition,” or “specific to” refer to measurable and reproducible interactions, such as the binding between a target and an antigen-binding protein (such as a CAR or VHH domain), which determines the presence of the target in the presence of a heterogeneous population of molecules containing biomolecules.

[0048] The term "specificity" refers to the selective recognition of a specific epitope of an antigen by an antigen-binding protein (such as a CAR or VHH domain). For example, natural antibodies are single-specific.

[0049] The term "expression" refers to the permission or initiation of the production of information from a gene or DNA sequence. For example, expression can take the form of producing a protein by activating cellular functions involved in the transcription and translation of the corresponding gene or DNA sequence. DNA sequences are expressed in or through cells to form "expression products," such as proteins. It is claimed that the expression products themselves, such as the resulting proteins, can also be "expressed" by cells. Expression products can be characterized as intracellular, extracellular, or transmembrane.

[0050] The term “treatment” refers to a therapeutic approach in which the treatment will slow or alleviate undesirable physiological changes or disease, or provide a beneficial or desired clinical outcome during treatment. Beneficial or desired clinical outcomes include symptom reduction, disease severity decrease, stable (i.e., no worsening) state of disease, delay or slowing of disease progression, improvement or mitigation of disease status, and / or remission (whether partial or complete), whether detectable or undetectable. “Treatment” may also mean an extension of survival compared to the expected survival of a subject without treatment. Subjects requiring treatment include those who already have undesirable physiological changes or disease, and those who are predisposed to developing such changes or disease. Treatment may involve therapeutic agents, also referred to herein as “medications” or “pharmaceuticals,” which may be designed to help achieve the desired or desired clinical outcome through their action. Therapeutic agents or drugs can be administered to subjects via many routes, including at least intravenous and oral routes. The term “intravenous” in relation to the administration of a therapeutic agent or drug means administration of the therapeutic agent or drug into one or more veins. The term "oral" in relation to the administration of a therapeutic agent or drug refers to the administration of the therapeutic agent or drug via an oral passage (such as the mouth).

[0051] As used herein, the term "subject" refers to an animal. The terms "subject" and "patient" are used interchangeably in this document when referring to a subject. Therefore, "subject" includes a person who is a patient receiving treatment for or preventing a disease. The methods described herein can be used to treat animal subjects belonging to any classification. Examples of such animals include mammals. Mammals include, but are not limited to, mammals of the order Rodentia (such as mice and hamsters) and mammals of the order Logomorpha (such as rabbits). Mammals can be of the order Carnivora, including felines (cats) and canines (dogs). Mammals can be of the order Artiodactyla, including bovids (cows) and suidae (pigs), or of the order Perssodactyla, including equines (horses). Mammals can be of the order Primate, order Ceboid, or order Simoid (monkeys), or of the order Anthropoid (humans and apes). In some embodiments, the mammal is a human.

[0052] The polynucleotide sequence encoding the CAR described herein can be obtained using standard recombinant techniques. The desired polynucleotide sequence can be isolated and sequenced from antibody-producing cells such as hybridoma cells. Alternatively, the polynucleotide can be synthesized using a nucleotide synthesizer or PCR technology. This disclosure also provides a vector containing a nucleic acid sequence encoding the CAR disclosed herein. The vector can be, for example, a plasmid, a granulosome, a viral vector (e.g., a retrovirus or adenovirus), an artificial chromosome (such as a yeast artificial chromosome (YAC), a bacterial artificial chromosome (BAC), or a P1-derived artificial chromosome (PAC)), or a bacteriophage. Suitable vectors and methods for vector preparation are well known in the art (see, for example, Sambrook et al. and Ausubel et al.).

[0053] In addition to the nucleic acid sequence encoding the CAR disclosed herein, the vector preferably contains expression control sequences that provide expression of the nucleic acid sequence in the host cell, such as promoters, enhancers, polyadenylation signals, transcription terminators, internal ribosome entry sites (IRES), etc. Exemplary expression control sequences are known in the art and described, for example, in Goeddel, Gene Expression Technology: Methods in Enzymology, Vol. 185, Academic Press, San Diego, Calif. (1990).

[0054] In some embodiments, the vector contains a promoter. A large number of promoters recognized by a variety of potential host cells are well known. The selected promoter can be operatively linked to cis-trans DNA encoding the CAR disclosed herein by means of digestion with a restriction enzyme to remove the promoter from the source DNA and inserting the isolated promoter sequence into the vector of this application. A large number of promoters from a variety of different sources, including constitutive, inducible, and repressive promoters, are well known in the art. Representative promoter sources include, for example, viruses, mammals, insects, plants, yeast, and bacteria, and suitable promoters from these sources are readily available or can be prepared synthetically based on sequences disclosed, for example, from repositories such as ATCC and other commercial or individual sources. The promoter can be unidirectional (i.e., initiating transcription in one direction) or bidirectional (i.e., initiating transcription in the 3' or 5' direction). Non-limiting examples of promoters include, for example, the T7 bacterial expression system, the pBAD(araA) bacterial expression system, the cytomegalovirus (CMV) promoter, the SV40 promoter, and the RSV promoter. Inducible promoters include, for example, the Tet system (US Patents 5,464,758 and 5,814,618), the ecdysone-inducible system (No et al., Proc. Natl. Acad. Sci., 93: 3346-3351 (1996)), and T-REX.™ System (Invitrogen, Carlsbad, CA), LACSWITCH ™ The system (Stratagene, San Diego, CA) and the Cre-ERT tamoxifen-inducible recombinase system (Indra et al., Nuc. Acid. Res., 27: 4324-4327 (1999); Nuc. Acid. Res., 28: e99 (2000); U.S. Patent 7,112,715; and Kramer & Fussenegger, Methods Mol. Biol, 308: 123-144 (2005)).

[0055] In some implementations, the vector contains an "enhancer". As used herein, the term "enhancer" refers to a DNA sequence that increases transcription, for example, a nucleic acid sequence operatively linked thereto. An enhancer can be located at numerous kilograms of a coding region remote from the nucleic acid sequence and can mediate the binding of regulatory factors, patterns of DNA methylation, or changes in DNA structure. Many enhancers from a variety of different sources are well known in the art and are available as clonal polynucleotides or from clonal polynucleotides (e.g., from repositories such as ATCC and other commercial or independent sources). Many promoter-containing polynucleotides (such as the commonly used CMV promoter) also contain enhancer sequences. Enhancers can be located upstream, inside, or downstream of the coding sequence. The term "Ig enhancer" refers to an enhancer element derived from an enhancer region located within an immunoglobulin (Ig) gene locus. Such Ig enhancers include, for example, heavy chain (μ) 5' enhancers, light chain (κ) 5' enhancers, κ and μ intron enhancers, and 3' enhancers (see generally Paul WE (ed.), Fundamental Immunology, 3rd ed., Raven Press, New York (1993), pp. 353-363; and U.S. Patent 5,885,827).

[0056] In some implementations, the vector contains a “selectable marker gene.” As used herein, the term “selectable marker gene” refers to a nucleic acid sequence that allows cells expressing the nucleic acid sequence to specifically select for or target a nucleic acid sequence in the presence of a suitable selector. Suitable alternative marker genes are known in the art and described, for example, in international patent applications published WO1992 / 08796 and WO 1994 / 28143; Wigler et al., Proc. Natl. Acad. Sci. USA, 77: 3567 (1980); O'Hare et al., Proc. Natl. Acad. Sci. USA, 78: 1527 (1981); Mulligan & Berg, Proc. Natl. Acad. Sci. USA, 78: 2072 (1981); Colberre-Garapin et al., J. Mol. Biol., 150: 1 (1981); Santerre et al., Gene, 30: 147 (1984); Kent et al., Science, 237: 901-903 (1987); Wigler et al., Cell, IP.223 (1977); Szybalska & Szybalski, Proc. Natl. Acad. Sci. USA, 48: 2026 (1962); Lowy et al., Cell, 22: 817 (1980); and U.S. Patents 5,122,464 and 5,770,359.

[0057] In some implementations, the vector is an "attachment expression vector" or "attachment" that can replicate in the host cell and persist as an extrachromosomal segment of DNA within the host cell under appropriate selective pressure (see, for example, Conese et al., Gene Therapy, 11: 1735-1742 (2004)). Representative commercially available attachment expression vectors include, but are not limited to, attachment plasmids utilizing Epstein Barr nuclear antigen 1 (EBNA1) and the Epstein Barr virus (EBV) origin of replication (oriP). Vectors pREP4, pCEP4, pREP7, and pcDNA3.1 from Invitrogen (Carlsbad, CA) and pB-CMV from Stratagene (La Jolla, CA) represent non-limiting examples of attachment vectors using T antigen and SV40 origin of replication instead of EBNA1 and oriP.

[0058] In some implementations, the vector is an "integrative expression vector" that can be randomly integrated into the host cell's DNA, or may contain recombination sites to allow recombination between the expression vector and specific sites in the host cell's chromosomal DNA. Such integrative expression vectors can utilize endogenous expression control sequences of the host cell's chromosome to achieve the expression of the desired protein. Examples of site-specifically integrated vectors include components of the flp-in system (e.g., pcDNA) from Ingenium Inc., Carlsbad, California. ™ 5 / FRT) or cre-lox systems, such as the pExchange-6 core vector from Stratagene, La Jolla, California. Examples of vectors that integrate randomly into the host cell chromosome include, for example, pcDNA3.1 from Ingenium, Carlsbad, California (when introduced in the absence of the T antigen) and pCI or pFNI OA (ACT) FLEXI from Promega (Madison, WI) in Madison, Wisconsin. ™ In some implementations, the integrative expression vector may also include components that facilitate its entry into cells, such as viral particles, liposomes, or protein coats, but are not limited to these substances.

[0059] In some embodiments, the vector is a viral vector. Representative viral expression vectors include, but are not limited to, adenovirus-based vectors (e.g., the adenovirus-based Per.C6 system available from Crucell, Inc. (Leiden, The Netherlands), lentivirus-based vectors (e.g., the lentivirus-based pLP1 from Technologies (Carlsbad, CA),) and retroviral vectors (e.g., pFB-ERV plus pCFB-EGSH from Stratagene, La Jolla, California). In some embodiments, the viral vector is a lentiviral vector. In some embodiments, the virus (such as lentivirus or adenovirus) refers to the complete virus, including the viral capsid and the viral vector contained within the viral capsid.

[0060] Vectors containing the nucleic acid of the present invention encoding a CAR can be introduced into host cells that can express the CAR encoded therefrom, including any suitable prokaryotic or eukaryotic cells. Preferred host cells are those that can be easily and reliably grown, have a reasonably rapid growth rate, possess a well-characterized expression system, and can be easily and efficiently transformed or transfected.

[0061] As used herein, the term "host cell" refers to any type of cell that may contain an expression vector. Host cells can be eukaryotic cells (e.g., plants, animals, fungi, or algae) or prokaryotic cells (e.g., bacteria or protozoa). Host cells can be cultured cells or primary cells (i.e., directly isolated from an organism (e.g., humans)). Host cells can be adherent cells or suspension cells, i.e., cells grown in suspension. Suitable host cells are known in the art and include, for example, DH5α *E. coli* cells, Chinese hamster ovary cells, monkey VERO cells, COS cells, HEK 293 cells, etc. In a preferred aspect, the host cell is HEK 293 cells. In some embodiments, HEK293 cells are derived from the ATCC SD-3515 line. In some embodiments, HEK 293 cells are derived from the IU-VPF MCB line. In some embodiments, HEK 293 cells are derived from the IU-VPF MWCB line. In some embodiments, the host cell is HEK293F cells. In some embodiments, the host cell may be a peripheral blood lymphocyte (PBL), a peripheral blood mononuclear cell (PBMC), or a natural killer (NK) cell. Preferably, the host cell is a natural killer (NK) cell. More preferably, the host cell is a T cell. In some embodiments, the host cell is an autologous cell.

[0062] For amplification or replication of recombinant expression vectors, host cells can be prokaryotic cells, such as DH5α cells. For production of virus from viral expression vectors, host cells can be eukaryotic cells, such as HEK 293 cells. For production of recombinant CARs, host cells can be mammalian cells. Host cells are preferably human cells. Host cells can be any cell type, can be derived from any type of tissue, and can be at any developmental stage. Methods for selecting suitable mammalian host cells and methods for transforming, culturing, amplifying, screening, and purifying cells are known in the art.

[0063] In some embodiments, the host cell is a T cell. The T cell disclosed herein can be any T cell, such as cultured T cells (e.g., primary T cells), T cells derived from cultured T cell lines, or T cells obtained from mammals. If obtained from mammals, the T cell can be obtained from a variety of sources, including but not limited to blood, bone marrow, lymph nodes, thymus, or other tissues or fluids. The T cell can also be enriched or purified. The T cell is preferably a human T cell (e.g., isolated from a human). The T cell can be at any developmental stage, including but not limited to CD4+ / CD8+ double-positive T cells, CD4+ helper T cells (e.g., Th and Th2 cells), CD8+ T cells (e.g., cytotoxic T cells), tumor-infiltrating cells, memory T cells, primordial T cells, etc. In one embodiment, the T cell is a CD8+ T cell or a CD4+ T cell. T cell lines can be obtained from, for example, the American Type Culture Collection (ATCC, Manassas, VA) and the German Collection of Microbial and Cell Cultures (DSMZ), and include, for example, Jurkat cells (ATCC TIB-152), Sup-Tl cells (ATCC CRL-1942), RPMI 8402 cells (DSMZ ACC-290), Karpas 45 cells (DSMZ ACC-545), and their derivatives.

[0064] In some implementations, the host cell is a natural killer (NK) cell. NK cells are a class of cytotoxic lymphocytes that function in the innate immune system. NK cells are defined as large granular lymphocytes and constitute the third cell type that differentiates from a common lymphoprogenitor cell, which also produces B lymphocytes and T lymphocytes (see, for example, *Immunobiology*, 5th edition, edited by Janeway et al., Garland Publishing, New York, NY (2001)). NK cells differentiate and mature in the bone marrow, lymph nodes, spleen, tonsils, and thymus. Upon maturation, NK cells enter circulation as large lymphocytes with distinctive cytotoxic granules. NK cells are able to recognize and kill some abnormal cells, such as some tumor cells and virus-infected cells, and are considered important in the innate immune defense against intracellular pathogens. As described above in contrast to T cells, NK cells can be any type of NK cell, such as cultured NK cells (e.g., primary NK cells), NK cells derived from cultured NK cell lines, or NK cells obtained from mammals. If derived from mammals, NK cells can be obtained from a variety of sources, including but not limited to blood, bone marrow, lymph nodes, thymus, or other tissues or fluids. NK cells can also be enriched or purified. NK cells are preferably human NK cells (e.g., isolated from humans). NK cell lines can be obtained, for example, from the American Type Culture Collection (ATCC, Manassas, VA), and include, for example, NK-92 cells (ATCC CRL-2407), NK92MI cells (ATCC CRL-2408), and their derivatives.

[0065] In some implementations, the nucleic acid sequence encoding the CAR can be introduced into the cell via “transfection,” “transformation,” or “transduction.” As used herein, “transfection,” “transformation,” or “transduction” refers to the introduction of one or more exogenous polynucleotides into a host cell using physical or chemical methods. Many transfection techniques are known in the art and include, for example, calcium phosphate DNA coprecipitation (see, for example, Murray EJ (ed.), Methods in Molecular Biology, Vol. 7, GeneTransfer and Expression Protocols, Humana Press (1991)); DEAE-dextran; electroporation; cationic liposome-mediated transfection; tungsten particle-promoted microparticle bombardment (Johnston, Nature, 346: 776-777 (1990)); and strontium phosphate DNA coprecipitation (Brash et al., Mol. Cell Biol., 7: 2031-2034 (1987)). After infectious particles have grown in suitable packaging cells, phage vectors or viral vectors can be introduced into host cells, many of which are commercially available.

[0066] The embodiments described herein relate to improved methods for manufacturing T-cell compositions and pharmaceutical products, particularly CAR-T cell pharmaceutical products. The manufacture of CAR-T cell pharmaceutical products is a complex, multi-day process. CAR-T cell manufacturing methods have been described, for example, in Hollyman et al., J. Immunother. 2009, 32:169-180, U.S. Patent Publication 2022 / 0195060A1, and U.S. Patent Publication 2022 / 0017862A1, each of which is incorporated herein by reference in its entirety.

[0067] A crucial step in manufacturing CAR-T cell therapy products is providing lentiviruses to transduce enriched T cells. The transduced T cells then produce and express the CAR protein, thus forming CAR-T cells. Lentiviral production itself is a complex, multi-day process, typically divided into upstream and downstream processing. Upstream processing establishes production, while downstream processing harvests and prepares the lentiviruses.

[0068] Figure 1An overview of the lentivirus manufacturing process is provided. Not wishing to be bound by theory, upstream processing can typically be broken down into two stages: 1) pre-culture and amplification, which can potentially take up to 22 days, and 2) bioreactor production, which can potentially take up to 4 days. The embodiments described herein relate to an improved transfection method that allows for a shorter timeframe from transfection to harvest (i.e., the bioreactor production stage), reduced impurity levels, and minimal loss in the quality or quantity of the final lentivirus product at harvest. In some embodiments, the method includes modifying the ratio of the vector used in the transduction process. In some embodiments, the method includes shortening the time from transduction to harvest. In some embodiments, the method includes both modifying the vector ratio and shortening the time from transduction to harvest.

[0069] This article provides a transfection composition comprising a four-vector lentiviral system, a method for preparing lentiviruses for manufacturing chimeric antigen receptor CAR-T drug products, a method for manufacturing CAR-T drug products, and a method for treating multiple myeloma.

[0070] Transfection composition

[0071] This document provides transfection compositions comprising a four-carrier system. In some embodiments, the four-carrier system comprises a first carrier, a second carrier, a third carrier, a fourth carrier, and a transfection medium.

[0072] In some embodiments, the first vector contains a polynucleotide encoding a target gene (GOI). In some embodiments, the polynucleotide encodes a chimeric antigen receptor (CAR). In some embodiments, the first vector contains a nucleic acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the following nucleic acid sequences:

[0073] Figure 2A The vectors depicted in the diagram are referred to herein as “GOI” vectors or “LLV” vectors. In some embodiments, the CAR encoded by the first vector is an immune-specific CAR that targets B cell maturation antigen (BCMA).

[0074] In some embodiments, the second vector contains a polynucleotide encoding a lentiviral envelope protein. In some embodiments, the lentiviral envelope protein is vesicular stomatitis virus G (VSVG). In some embodiments, the VSVG envelope pseudotyped lentiviral vector extends the target cell tropism range of the vector and increases the stability of the lentiviral vector, thereby allowing for lentiviral concentration by high-speed centrifugation and further obtaining higher titers. In some embodiments, the second vector contains a nucleic acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the following nucleic acid sequences:

[0075] Figure 2B The vector shown in the diagram is referred to herein as the "MD2.G" vector.

[0076] In some embodiments, the third vector contains polynucleotides containing GAG and POL. In some embodiments, the third vector also contains a REV protein binding site. In some embodiments, the Gag gene encodes major structural proteins of the viral particle, such as nucleocapsid proteins, membrane proteins, and capsid proteins. In some embodiments, the pol gene encodes viral replication-related enzymes, such as proteases, reverse transcriptases, and integrases. In some embodiments, the third vector contains a nucleic acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the following nucleic acid sequences:

[0077] Figure 2C The vector shown in the diagram is referred to herein as the "MDLg" vector.

[0078] In some embodiments, the fourth vector contains a polynucleotide encoding REV. In some embodiments, the Rev gene controls the expression levels of the Gag and Pol genes and guides the replication of single-stranded DNA, and can regulate splicing / RNA transport. In some embodiments, the fourth vector contains a nucleic acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the following nucleic acid sequences:

[0079] Figure 2D The vector shown in the diagram is referred to herein as the "RSV-REV" vector.

[0080] In some implementations, the transfection medium is selected from any suitable transfection medium or culture medium, such as T cell growth medium (TCGM) or CTS. ™ LV-MAX ™ Production culture medium (Thermo Fischer).

[0081] In some embodiments, the first carrier (“GOI”), the second carrier (“MD2.G”), the third carrier (“MDLg”), and the fourth carrier (“RSV-REV”) are included in the transfection composition in a certain ratio. In some embodiments, the ratio of the first, second, third, and fourth carriers is an A:B:C:D ratio, where A represents the value of the first carrier, B represents the value of the second carrier, C represents the value of the third carrier, and D represents the value of the fourth carrier. In some embodiments, A represents a value of 2 to about 16, B represents a value of about 1 to about 5, C represents a value of about 1 to about 5, and D represents a value of about 1 to about 5.

[0082] In some embodiments, the first carrier exists in the ratio with a value ranging from about 2 to about 16. In some embodiments, the first carrier exists in the ratio with a value of about 2. In some embodiments, the first carrier exists in the ratio with a value of about 3. In some embodiments, the first carrier exists in the ratio with a value of about 4. In some embodiments, the first carrier exists in the ratio with a value of about 5. In some embodiments, the first carrier exists in the ratio with a value of about 6. In some embodiments, the first carrier exists in the ratio with a value of about 7. In some embodiments, the first carrier exists in the ratio with a value of about 8. In some embodiments, the first carrier exists in the ratio with a value of about 9. In some embodiments, the first carrier exists in the ratio with a value of about 10. In some embodiments, the first carrier exists in the ratio with a value of about 11. In some embodiments, the first carrier exists in the ratio with a value of about 12. In some embodiments, the first carrier exists in the ratio with a value of about 13. In some embodiments, the first carrier exists in the ratio with a value of about 14. In some embodiments, the first carrier exists in the ratio with a value of about 15. In some embodiments, the first carrier exists in the ratio with a value of about 16.

[0083] In some embodiments, the second carrier is present in the ratio at a value ranging from about 1 to about 5. In some embodiments, the second carrier is present in the ratio at a value of about 2. In some embodiments, the second carrier is present in the ratio at a value of about 3. In some embodiments, the second carrier is present in the ratio at a value of about 4. In some embodiments, the second carrier is present in the ratio at a value of about 5.

[0084] In some embodiments, the third carrier is present in the ratio at a value ranging from about 1 to about 5. In some embodiments, the third carrier is present in the ratio at a value of about 2. In some embodiments, the third carrier is present in the ratio at a value of about 3. In some embodiments, the third carrier is present in the ratio at a value of about 4. In some embodiments, the third carrier is present in the ratio at a value of about 5.

[0085] In some embodiments, the fourth carrier is present in the ratio at a value ranging from about 1 to about 5. In some embodiments, the fourth carrier is present in the ratio at a value of about 2. In some embodiments, the fourth carrier is present in the ratio at a value of about 3. In some embodiments, the fourth carrier is present in the ratio at a value of about 4. In some embodiments, the fourth carrier is present in the ratio at a value of about 5.

[0086] In some implementations, the first, second, third, and fourth carriers are in the ratio 2-16:1-5:1-5:1-5, such as 2-11:1-3:1:1-5, 2-10:1-3:1:1-5, 2-9:1-3:1:1-5, 2-8:1-3:1:1-5, 2-7:1-3:1:1-5, 2-6:1-3:1:1-5, 2-5:1-3:1:1-5, 2-4:1-3:1:1-5, 2-3:1-3:1:1-5, 2-7:1-3:1:1-5, 3-12: 1-3:1:1-5, 3-11:1-3:1:1-5, 3-10:1-3:1:1-5, 3-9:1-3:1:1-5, 3-8:1-3:1:1-5, 3-7:1-3:1:1-5, 3-6:1-3:1:1-5, 3-5:1-3:1:1-5, 3-4:1-3:1:1-5, 4-12:1-3:1:1-5, 4-11:1-3:1:1-5, 4-10:1-3:1:1-5, 4-9:1-3:1:1-5, 4-8:1-3:1:1- 5, 4-7:1-3:1:1-5, 4-6:1-3:1:1-5, 4-5:1-3:1:1-5, 5-12:1-3:1:1-5, 5-11:1-3:1:1-5, 5-10:1-3:1:1-5, 5-9:1-3:1:1-5, 5-8:1-3:1:1-5, 5-7:1-3:1:1-5, 5-6:1-3:1:1-5, 6-12:1-3:1:1-5, 7-12:1-3:1:1-5, 7-11:1-3:1:1-5, 7-10: The ratios 1-3:1:1-5, 7-9:1-3:1:1-5, 7-8:1-3:1:1-5, 8-12:1-3:1:1-5, 8-11:1-3:1:1-5, 8-10:1-3:1:1-5, 8-9:1-3:1:1-5, 9-12:1-3:1:1-5, 9-11:1-3:1:1-5, 9-10:1-3:1:1-5, 10-12:1-3:1:1-5, 10-11:1-3:1:1-5, and 11-12:1-3:1:1-5 exist. In some implementations, the first carrier, the second carrier, the third carrier, and the fourth carrier are present in a ratio of 2-12:1-3:1:1-5, such as 2-12:1-2:1:1-5 or 2-12:2-3:1:1-5.In some implementations, the first carrier, the second carrier, the third carrier, and the fourth carrier exist in a ratio of 2-12:1-3:1:1-5, such as 2-12:1-3:1:1-4, 2-12:1-3:1:1-3, 2-12:1-3:1:1-2, 2-12:1-3:1:2-5, 2-12:1-3:1:2-4, 2-12:1-3:1:2-3, 2-12:1-3:1:3-5, 2-12:1-3:1:3-4, and 2-12:1-3:1:4-5.

[0087] In some implementation schemes, the first carrier, second carrier, third carrier, and fourth carrier are in the ratios of 6:4:5:5, 6:5:4:5, 6:5:5:4, 8:2:5:5, 8:3:4:5, 8:3:5:4, 8:4:4:4, 8:4:5:3, 8:5:2:5, 8:5:3:4, 8:5:4:3, 8:5:5:2, and 9:5:1: 5, 10:1:4:5, 10:1:5:4, 10:2:3:5, 10:2:4:4, 10:2:5:3, 10:3:2:5, 10:3:5:2, 10:4:1:5, 10:4:2:4, 10:4:4:2, 10:4:5:1, 10:5:1:4, 10:5:2:3, 10:5:3:2, 10: 5:4:1, 11:3:1:5, 12:1:2:5, 12:1:3:4, 12:1:4:3, 12:1:5:2, 12:2:1:5, 12:2:2:4, 12:2:5:1, 12:3:1:4, 12:3:4:1, 12:4:1:3, 12:4:2:2, 12:4:3:1, 12:5:1:2 The ratios of the first, second, third, and fourth carriers are 12:5:2:1, 13:1:1:5, 14:1:1:4, 14:1:2:3, 14:1:3:2, 14:1:4:1, 14:2:1:3, 14:2:3:1, 14:3:1:2, 14:3:2:1, 14:4:1:1, 16:1:1:2, 16:1:2:1, or 16:2:1:1. In some embodiments, the first, second, third, and fourth carriers are in a ratio of 6:4:5:5. In some embodiments, the first, second, third, and fourth carriers are in a ratio of 6:5:4:5. In some embodiments, the first, second, third, and fourth carriers are in a ratio of 6:5:5:4. In some embodiments, the first, second, third, and fourth carriers are in a ratio of 8:2:5:5. In some embodiments, the first carrier, second carrier, third carrier, and fourth carrier are present in a ratio of 8:3:4:5. In some embodiments, the first carrier, second carrier, third carrier, and fourth carrier are present in a ratio of 8:3:5:4. In some embodiments, the first carrier, second carrier, third carrier, and fourth carrier are present in a ratio of 8:4:4:4. In some embodiments, the first carrier, second carrier, third carrier, and fourth carrier are present in a ratio of 8:4:5:3. In some embodiments, the first carrier, second carrier, third carrier, and fourth carrier are present in a ratio of 8:5:2:5. In some embodiments, the first carrier, second carrier, third carrier, and fourth carrier are present in a ratio of 8:5:3:4. In some embodiments, the first carrier, second carrier, third carrier, and fourth carrier are present in a ratio of 8:5:4:3.In some embodiments, the first, second, third, and fourth carriers are present in a ratio of 8:5:5:2. In some embodiments, the first, second, third, and fourth carriers are present in a ratio of 9:5:1:5. In some embodiments, the first, second, third, and fourth carriers are present in a ratio of 10:1:4:5. In some embodiments, the first, second, third, and fourth carriers are present in a ratio of 10:1:5:4. In some embodiments, the first, second, third, and fourth carriers are present in a ratio of 10:2:3:5. In some embodiments, the first, second, third, and fourth carriers are present in a ratio of 10:2:4:4. In some embodiments, the first, second, third, and fourth carriers are present in a ratio of 10:2:5:3. In some embodiments, the first, second, third, and fourth carriers are present in a ratio of 10:3:2:5. In some embodiments, the first, second, third, and fourth carriers are present in a ratio of 10:3:5:2. In some embodiments, the first, second, third, and fourth carriers are present in a ratio of 10:4:1:5. In some embodiments, the first, second, third, and fourth carriers are present in a ratio of 10:4:2:4. In some embodiments, the first, second, third, and fourth carriers are present in a ratio of 10:4:4:2. In some embodiments, the first, second, third, and fourth carriers are present in a ratio of 10:4:5:1. In some embodiments, the first, second, third, and fourth carriers are present in a ratio of 10:5:1:4. In some embodiments, the first, second, third, and fourth carriers are present in a ratio of 10:5:2:3. In some embodiments, the first, second, third, and fourth carriers are present in a ratio of 10:5:3:2. In some embodiments, the first, second, third, and fourth carriers are present in a ratio of 10:5:4:1. In some embodiments, the first, second, third, and fourth carriers are present in a ratio of 11:3:1:5. In some embodiments, the first, second, third, and fourth carriers are present in a ratio of 12:1:2:5. In some embodiments, the first, second, third, and fourth carriers are present in a ratio of 12:1:3:4. In some embodiments, the first, second, third, and fourth carriers are present in a ratio of 12:1:4:3. In some embodiments, the first, second, third, and fourth carriers are present in a ratio of 12:1:5:2. In some embodiments, the first, second, third, and fourth carriers are present in a ratio of 12:2:1:5.In some embodiments, the first, second, third, and fourth carriers are present in a ratio of 12:2:2:4. In some embodiments, the first, second, third, and fourth carriers are present in a ratio of 12:2:5:1. In some embodiments, the first, second, third, and fourth carriers are present in a ratio of 12:3:1:4. In some embodiments, the first, second, third, and fourth carriers are present in a ratio of 12:3:4:1. In some embodiments, the first, second, third, and fourth carriers are present in a ratio of 12:4:1:3. In some embodiments, the first, second, third, and fourth carriers are present in a ratio of 12:4:2:2. In some embodiments, the first, second, third, and fourth carriers are present in a ratio of 12:4:3:1. In some embodiments, the first, second, third, and fourth carriers are present in a ratio of 12:5:1:2. In some embodiments, the first, second, third, and fourth carriers are present in a ratio of 12:5:2:1. In some embodiments, the first, second, third, and fourth carriers are present in a ratio of 13:1:1:5. In some embodiments, the first, second, third, and fourth carriers are present in a ratio of 14:1:1:4. In some embodiments, the first, second, third, and fourth carriers are present in a ratio of 14:1:2:3. In some embodiments, the first, second, third, and fourth carriers are present in a ratio of 14:1:3:2. In some embodiments, the first, second, third, and fourth carriers are present in a ratio of 14:1:4:1. In some embodiments, the first, second, third, and fourth carriers are present in a ratio of 14:2:1:3. In some embodiments, the first, second, third, and fourth carriers are present in a ratio of 14:2:3:1. In some embodiments, the first, second, third, and fourth carriers are present in a ratio of 14:3:1:2. In some embodiments, the first, second, third, and fourth carriers are present in a ratio of 14:3:2:1. In some embodiments, the first, second, third, and fourth carriers are present in a ratio of 14:4:1:1. In some embodiments, the first, second, third, and fourth carriers are present in a ratio of 16:1:1:2. In some embodiments, the first, second, third, and fourth carriers are present in a ratio of 16:1:2:1. In some embodiments, the first, second, third, and fourth carriers are present in a ratio of 16:2:1:1.

[0088] In some embodiments, the first, second, third, and fourth carriers are present in a ratio of 2:1:1:1, 11:3:1:5, or 12:2:1:5. In some embodiments, the first, second, third, and fourth carriers are present in a ratio of 2:1:1:1. In some embodiments, the ratio of the first, second, third, and fourth carriers is 11:3:1:5. In some embodiments, the ratio of the first, second, third, and fourth carriers is 12:2:1:5.

[0089] method

[0090] In some embodiments, lentiviruses are provided for preparing chimeric antigen receptor (CAR) T-cell (CAR-T) drug products. In some embodiments, the method includes transfecting host cells with a transfection composition, culturing the transfected host cells to proliferate, and harvesting the lentivirus. In some embodiments, the transfection composition is any transfection composition provided herein. In some embodiments, the transfection composition comprises a first vector, a second vector, a third vector, and a fourth vector. In some embodiments, the vectors in the transfection composition are present in a specific ratio. In some embodiments, the vector ratio is any vector ratio provided herein.

[0091] In some embodiments, the time from transfecting host cells to harvesting lentivirus is less than or equal to about 48 hours. In some embodiments, the time from transfecting host cells to harvesting lentivirus is less than or equal to about 36 hours. In some embodiments, the time from transfecting host cells to harvesting lentivirus is less than or equal to about 24 hours. In some embodiments, the time from transfecting host cells to harvesting lentivirus is 22-26 hours, 23-25 ​​hours, 23-34 hours, 23.5 to 24.5 hours, or 24-25 hours. In some embodiments, the time from transfecting host cells to harvesting lentivirus is about 24 hours. In some embodiments, the time from transfecting host cells to harvesting lentivirus is 24 hours.

[0092] In some embodiments, the carrier ratio is 2:1:1:1, and harvest occurs approximately 24 hours post-transfection. In some embodiments, the carrier ratio is 11:3:1:5, and harvest occurs approximately 48 hours post-transfection. In some embodiments, the carrier ratio is 11:3:1:5, and harvest occurs approximately 24 hours post-transfection. In some embodiments, the carrier ratio is 12:2:1:5, and harvest occurs approximately 48 hours post-transfection. In some embodiments, the carrier ratio is 12:2:1:5, and harvest occurs approximately 24 hours post-transfection.

[0093] In some embodiments, the cultivation is carried out in a bioreactor. In some embodiments, the bioreactor is a 2L, 10L, or 50L bioreactor. In some embodiments, the bioreactor is a shake flask.

[0094] In some embodiments, a method for manufacturing a CAR-T drug product is provided. In some embodiments, the CAR-T drug product is a BCMA CAR-T drug product. In some embodiments, the method for manufacturing a CAR-T drug product includes: providing activated T cells from apheresis material from a subject, contacting the T cells with a lentivirus prepared by any method disclosed herein or by using any transfection composition disclosed herein, culturing the transfected T cells to proliferate, and harvesting the CAR-T drug product.

[0095] In some embodiments, the CAR-T cell drug product generated during the execution of the methods described herein expresses one or more chimeric antigen receptors (CARs) on its surface. Typically, a CAR comprises an extracellular domain, a transmembrane domain, and an intracellular signaling domain, such as a primary signaling domain, and optionally one or more co-stimulatory domains, derived from a first protein (e.g., an antigen-binding protein). In a preferred embodiment, once the extracellular domain binds to a target protein, such as a tumor-associated antigen (TAA) or tumor-specific antigen (TSA), a signal is generated via the intracellular signaling domain to activate immune cells, for example, to target and kill cells expressing the target protein.

[0096] The extracellular domain of the CAR binds to the target antigen. In some embodiments, the extracellular domain of the CAR contains a receptor or a portion thereof that binds to the antigen. In some embodiments, the extracellular domain contains either an antibody or its antigen-binding portion. In some embodiments, the extracellular domain contains a single-chain Fv (scFv) domain or is a single-chain Fv domain. The single-chain Fv domain may contain, for example, a VL linked to a VH via a flexible linker, wherein the VL and VH are derived from an antibody binding the antigen. In some embodiments, the single-chain Fv domain may contain two VHH domains.

[0097] In some embodiments, the antigen recognized by the extracellular domain of the polypeptide described herein is a tumor-associated antigen (TAA) or a tumor-specific antigen (TSA). In various specific embodiments, the tumor-associated antigen or tumor-specific antigen is, but is not limited to, Her2, prostate stem cell antigen (PSCA), alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), cancer antigen-125 (CA-125), CA19-9, calreticulin, MUC-1, B-cell maturation antigen (BCMA), epithelial membrane protein (EMA), epithelial tumor antigen (ETA), tyrosinase, melanoma-24-associated antigen (MAGE), CD19, CD22, CD27, CD30, CD34, CD45, CD70, CD99, CD117, EGFRvIII (epidermal growth factor variant III), mesothelin, PAP (prostatic acid phosphatase), and prostate... Transmembrane proteins, TARP (T-cell receptor γ-alternating reading frame protein), Trp-p8, STEAPI (prostate six-transmembrane epithelial antigen 1), chromogranin, cytokeratin, desmin, glial fibrillary acidic protein (GFAP), macrocystic disease fluid protein (GCDFP-15), HMB-45 antigen, melanin-A protein (T lymphocyte-recognized melanoma antigen; MART-I), myo-D1, muscle-specific actin (MSA), neurofilaments, neuron-specific enolase (NSE), placental alkaline phosphatase, synaptophysin, thyroglobulin, thyroid transcription factor-1, pyruvate kinase isoenzyme M2 dimer form (tumor M2-PK), aberrant ras protein, or aberrant p53 protein. In some embodiments, the TAA or TSA recognized by the extracellular domain of CAR is integrin αvβ3 (CD61), galactagogue, or Ral-B.

[0098] In some implementations, the TAA or TSA recognized by the extracellular domain of the CAR is a cancer / testis (CT) antigen, such as BAGE, CAGE, CTAGE, FATE, GAGE, HCA661, HOM-TES-85, MAGEA, MAGEB, MAGEC, NA88, NY-ES0-1, NY-SAR-35, OY-TES-1, SPANXBI, SPA17, SSX, SYCPI, or TPTE.

[0099] In some implementations, the TAA or TSA recognized by the extracellular domain of the CAR is a carbohydrate or ganglioside, such as fuc-GMI, GM2 (carcinoembryonic antigen-immunogenic-1; OFA-I-1); GD2 (OFA-I-2), GM3, GD3, etc.

[0100] In some implementations, the TAA or TSA recognized by the extracellular domain of CAR is α-actin-4, Bage-1, BCR-ABL, Bcr-Abl fusion protein, β-catenin, CA 125, CA 15-3 (CA 27.29\BCAA), CA195, CA 242, CA-50, CAM43, Casp-8, cdc27, cdk4, cdkn2a, CEA, coa-1, dek-can fusion protein, EBNA, EF2, Epstein Barr virus antigen, ETV6-AML1 fusion protein, HLA-A2, HLA-A11, hsp70-2, KIAA0205, Mart2, Mum-1, 2 and 3, neo-PAP, myosin class I, OS-9, pml-RARα fusion protein, PTPRK, K-ras, N-ras, triose phosphate isomerase, Gage 3,4,5,6,7、GnTV、Herv-K-mel、Lage-1、NA-88、NY-Eso-1 / Lage-2、SP17、SSX-2、TRP2-Int2、gp100(Pmel17、tyrosinase、TRP-1、TRP-2、MAGE-1、MAGE-3、RAGE、GAGE-1、GAGE-2、p15(58)、RAGE、SCP-1、Hom / Mel-40, PRAME, p53, HRAs, HER-2 / neu, E2A-PRL, H4-RET, IGH-IGK, MYL-RAR, Human Papillomavirus (HPV) Antigens E6 and E7, TSP-180, MAGE-4, MAGE-5, MAGE-6, p185erbB2, p180erbB-3, c-met, nm-23H1, PSA, TAG-72-4, CA 19-9, CA 72-4, CAM 17.1, NuMa, K-ras, 13-catenin, Mum-1, p16, TAGE, PSMA, CT7, telomerase, 43-9F, 5T4, 791Tgp72, 13HCG, BCA225, BTAA, CD68 / KP1, CO-029, FGF-5, G250, Ga733 (EpCAM), HTgp-175, M344, MA-50, MG7-Ag, MOV18, NB / 70K, NY-CO-1, RCAS1, SDCCAG16, TA-90, TAAL6, TAG72, TLP or TPS. Other tumor-associated antigens and tumor-specific antigens are known to those skilled in the art.

[0101] Receptors, antibodies, and scFvs that bind to TSA and TAA and can be used to construct chimeric antigen receptors, as well as the nucleotide sequences encoding them, are known in the art.

[0102] In some specific embodiments, the antigen recognized by the extracellular domain of the chimeric antigen receptor is an antigen that is not normally considered a TSA or TAA, but it is still associated with tumor cells or tumor-induced damage. In some embodiments, for example, the antigen is a growth factor, cytokine, or interleukin, such as a growth factor, cytokine, or interleukin associated with angiogenesis or vascularization. Such growth factors, cytokines, or interleukins may include, for example, vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), platelet-derived growth factor (PDGF), hepatocyte growth factor (HGF), insulin-like growth factor (IGF), or interleukin-8 (IL-8). Tumors can also create a hypoxic environment locally. Therefore, in other specific embodiments, the antigen is a hypoxia-associated factor, such as HIF-1α, HIF-1β, HIF-2α, HIF-2β, HIF-3α, or HIF-3β. Tumors can also cause localized damage to normal tissues, thereby triggering the release of molecules known as damage-associated molecular pattern molecules (DAMPs; also called alarm molecules). Therefore, in some other specific implementations, the antigen is a DAMP, such as heat shock protein, high-mobility group 1 (HMGB 1), S100A8 (MRP8, cadherin A), S100A9 (MRP14, cadherin B), serum amyloid A (SAA), or it may be deoxyribonucleic acid, adenosine triphosphate, uric acid, or heparin sulfate.

[0103] In some embodiments, the extracellular domain of the CAR is linked to the transmembrane domain of the peptide via a linker, spacer region, or hinge peptide sequence (e.g., a sequence from CD28 or from CTLA4). The transmembrane domain can be derived from or derived from the transmembrane domain of any transmembrane protein and can include all or a portion of such a transmembrane domain. In specific embodiments, the transmembrane domain can be derived from, for example, CD8, CD16, cytokine receptors and interleukin receptors, or growth factor receptors.

[0104] Intracellular signaling domain: In some embodiments, the intracellular domain of the CAR is or is contained within an intracellular domain or motif of a protein expressed on or near the surface of a T cell and triggering the activation and / or proliferation of the T cell. This domain or motif can transmit a primary antigen-binding signal, which is necessary for the activation of T lymphocytes in response to the binding of an antigen to the extracellular portion of the CAR. Typically, this domain or motif contains or is an ITAM (an immune receptor tyrosine-based activation motif). Suitable ITAM-containing peptides for CARs include, for example, a ζCD3 chain (CD3ζ) or an ITAM-containing portion thereof. In one specific embodiment, the intracellular domain is or contains a CD3ζ intracellular signaling domain; the CD3ζ intracellular signaling domain may be referred to as the primary signaling domain. In other specific embodiments, the intracellular domain (primary signaling domain) is derived from a lymphocyte receptor chain, a TCR / CD3 complex protein, an Fc receptor subunit, or an IL-2 receptor subunit.

[0105] In some implementations, the CAR also includes one or more co-stimulatory domains or motifs, for example, as part of an intracellular domain of the peptide. The one or more co-stimulatory domains or motifs may be or may include one or more of the following: a co-stimulatory CD27 peptide sequence or domain, a co-stimulatory CD28 peptide sequence or domain, a co-stimulatory OX40 (CD134) peptide sequence or domain, a co-stimulatory 4-1BB (CD137) peptide sequence or domain, a co-stimulatory induced T cell co-stimulatory (ICOS) peptide sequence or domain, or other co-stimulatory domains or motifs, or any combination thereof.

[0106] CARs may also contain T-cell survival motifs. T-cell survival motifs can be any polypeptide sequence or motif that promotes T lymphocyte survival upon antigen stimulation. In some embodiments, the T-cell survival motif is or is derived from the intracellular signaling domains of CD3, CD28, the IL-7 receptor (IL-7R), the IL-12 receptor, the IL-15 receptor, the IL-21 receptor, or the transforming growth factor β (TGFβ) receptor.

[0107] In some embodiments, the CAR immune-specifically targets B cell maturation antigen (BCMA). In some embodiments, the immune-specific BCMA-targeting CAR-T drug product is Cilta-cel. “Cilta-cel” (“cilta-cel”) is a chimeric antigen receptor T-cell (CAR-T) therapy comprising two VHH domains targeting B cell maturation antigen (BCMA) that are engineered to confer affinity for BCMA. Cilta-cel may comprise T lymphocytes transduced with a Cilta-cel CAR (a CAR encoded by a lentiviral vector). The CAR targets human B cell maturation antigen (BCMA CAR). Cilta-cel is described, for example, in U.S. Patent Nos. 10,934,363 and 11,535,677, both of which are incorporated herein by reference in their entirety.

[0108] In some implementations, a method for treating multiple myeloma is provided, comprising administering a CAR-T drug product prepared by any of the methods disclosed herein.

[0109] Enumeration Implementation Plan

[0110] The following examples are illustrative and not limiting of the compounds, compositions, and methods described herein. Other suitable modifications and adjustments known to those skilled in the art are within the scope of the following embodiments.

[0111] 1. A method for preparing a lentivirus for manufacturing chimeric antigen receptor (CAR) T cell (CAR-T) drug products, the method comprising:

[0112] Transfecting host cells with a transfection composition, wherein the transfection composition comprises:

[0113] The first vector containing a polynucleotide encoding CAR

[0114] The second, third, and fourth carriers, and

[0115] Transfection medium;

[0116] The ratio of the first carrier to the second carrier to the third carrier to the fourth carrier is 2:1:1:1, 11:3:1:5, or 12:2:1:5.

[0117] Culture the transfected host cells to proliferate, and

[0118] Harvest the lentivirus, wherein the harvest occurs approximately 24 hours after transfection.

[0119] 2. A method for preparing a lentivirus for manufacturing chimeric antigen receptor (CAR) T cell (CAR-T) drug products, the method comprising:

[0120] Transfecting host cells with a transfection composition, wherein the transfection composition comprises:

[0121] The first vector containing a polynucleotide encoding CAR

[0122] The second, third, and fourth carriers, and

[0123] Transfection medium;

[0124] The ratio of the first carrier to the second carrier to the third carrier to the fourth carrier is 11:3:1:5 or 12:2:1:5.

[0125] Culture the transfected host cells to proliferate, and

[0126] Harvest the lentivirus, wherein the harvest occurs less than or equal to about 48 hours after transfection.

[0127] 3. The method according to implementation scheme 1, wherein the ratio is 2:1:1:1.

[0128] 4. The method according to implementation scheme 1 or 2, wherein the ratio is 11:3:1:5.

[0129] 5. The method according to implementation scheme 1 or 2, wherein the ratio is 12:2:1:5.

[0130] 6. The method according to any one of embodiments 3 to 5, wherein the harvest occurs approximately 24 hours after transfection.

[0131] 7. The method according to any one of embodiments 1 to 6, wherein the first vector, the second vector, the third vector and the fourth vector comprise lentiviral vectors.

[0132] 8. The method according to embodiment 1, wherein the ratio is 2:1:1:1, and the harvest occurs approximately 24 hours after transfection.

[0133] 9. The method according to embodiment 1, wherein the ratio is 11:3:1:5, and the harvest occurs approximately 24 hours after transfection.

[0134] 10. The method according to embodiment 1, wherein the ratio is 12:2:1:5, and the harvest occurs approximately 24 hours after transfection.

[0135] 11. The method according to any one of embodiments 1 to 10, wherein the second vector comprises a polynucleotide encoding a lentiviral envelope protein.

[0136] 12. The method according to embodiment 11, wherein the lentiviral envelope protein is vesicular stomatitis virus G (VSVG).

[0137] 13. The method according to any one of embodiments 1 to 12, wherein the third vector comprises polynucleotides encoding GAG and POL.

[0138] 14. The method according to any one of embodiments 1 to 13, wherein the fourth vector comprises a polynucleotide encoding REV.

[0139] 15. The method according to any one of embodiments 1 to 14, wherein the culture takes place in a bioreactor.

[0140] 16. The method according to embodiment 15, wherein the bioreactor is a 2L, 10L or 50L bioreactor.

[0141] 17. The method according to embodiments 1 to 16, wherein the host cell is a HEK 293 cell, such as a HEK293F cell.

[0142] 18. The method according to any one of embodiments 1 to 17, wherein the CAR immunely and specifically targets B cell maturation antigen (BCMA).

[0143] 19. A method for preparing a lentivirus for manufacturing BCMA CAR-T drug products, the method comprising:

[0144] Transfecting host cells with a transfection composition, wherein the transfection composition comprises:

[0145] A first vector, comprising a polynucleotide encoding a CAR that specifically targets BCMA.

[0146] The second, third, and fourth carriers, and

[0147] Transfection medium;

[0148] The ratio of the first carrier to the second carrier to the third carrier to the fourth carrier is 2:1:1:1, 11:3:1:5, or 12:2:1:5.

[0149] Culture the transfected host cells to proliferate, and

[0150] Harvest the lentivirus, wherein the harvest occurs approximately 24 hours after transfection.

[0151] 20. A method for preparing a lentivirus for manufacturing BCMA CAR-T drug products, the method comprising:

[0152] Transfecting host cells with a transfection composition, wherein the transfection composition comprises:

[0153] A first vector, comprising a polynucleotide encoding a CAR that specifically targets BCMA.

[0154] The second, third, and fourth carriers, and

[0155] Transfection medium;

[0156] The ratio of the first carrier to the second carrier to the third carrier to the fourth carrier is 11:3:1:5 or 12:2:1:5.

[0157] Culture the transfected host cells to proliferate, and

[0158] Harvest the lentivirus, wherein the harvest occurs less than or equal to about 48 hours after transfection.

[0159] 21. The method according to embodiment 19, wherein the ratio is 2:1:1:1.

[0160] 22. The method according to embodiment 19 or 20, wherein the ratio is 11:3:1:5.

[0161] 23. The method according to embodiment 19 or 20, wherein the ratio is 12:2:1:5.

[0162] 24. The method according to any one of embodiments 20 to 23, wherein the harvest occurs approximately 24 hours after transfection.

[0163] 25. The method according to any one of embodiments 19 to 24, wherein the first vector, the second vector, the third vector and the fourth vector comprise lentiviral vectors.

[0164] 26. The method according to embodiment 19, wherein the ratio is 2:1:1:1, and the harvest occurs approximately 24 hours after transfection.

[0165] 27. The method according to embodiment 19, wherein the ratio is 11:3:1:5, and the harvest occurs approximately 24 hours after transfection.

[0166] 28. The method according to embodiment 19, wherein the ratio is 12:2:1:5, and the harvest occurs approximately 24 hours after transfection.

[0167] 29. The method according to any one of embodiments 19 to 28, wherein the second vector comprises a polynucleotide encoding a lentiviral envelope protein.

[0168] 30. The method according to embodiment 29, wherein the lentiviral envelope protein is vesicular stomatitis virus G (VSVG).

[0169] 31. The method according to any one of embodiments 19 to 30, wherein the third vector comprises polynucleotides encoding GAG and POL.

[0170] 32. The method according to any one of embodiments 19 to 31, wherein the fourth vector comprises a polynucleotide encoding REV.

[0171] 33. The method according to any one of embodiments 19 to 32, wherein the culture takes place in a bioreactor.

[0172] 34. The method according to embodiment 33, wherein the bioreactor is a 2L, 10L or 50L bioreactor.

[0173] 35. The method according to any one of embodiments 19 to 34, wherein the host cell is a HEK 293 cell, such as a HEK 293F cell.

[0174] 36. The method according to any one of embodiments 19 to 35, wherein the first carrier comprises SEQ ID NO: 1.

[0175] 37. The method according to any one of embodiments 19 to 36, wherein the second carrier comprises SEQ ID NO: 2.

[0176] 38. The method according to any one of embodiments 19 to 37, wherein the third carrier comprises SEQ ID NO: 3.

[0177] 39. The method according to any one of embodiments 19 to 38, wherein the fourth carrier comprises SEQ ID NO: 4.

[0178] 40. The method according to any one of embodiments 19 to 39, wherein the CAR-T drug product is cilta-cel.

[0179] 41. A transfection composition comprising:

[0180] The first vector containing a polynucleotide encoding CAR

[0181] The second, third, and fourth carriers, and

[0182] Transfection medium;

[0183] The ratio of the first carrier to the second carrier to the third carrier to the fourth carrier is 2:1:1:1, 11:3:1:5, or 12:2:1:5.

[0184] 42. The transfection composition according to embodiment 41, wherein the ratio is 2:1:1:1.

[0185] 43. The transfection composition according to embodiment 41, wherein the ratio is 11:3:1:5.

[0186] 44. The transfection composition according to embodiment 14, wherein the ratio is 12:2:1:5.

[0187] 45. The transfection composition according to any one of embodiments 41 to 44, wherein the second vector comprises a polynucleotide encoding a lentiviral envelope protein.

[0188] 46. ​​The transfection composition according to embodiment 45, wherein the lentiviral envelope protein is vesicular stomatitis virus G (VSVG).

[0189] 47. The transfection composition according to any one of embodiments 41 to 46, wherein the third vector comprises polynucleotides encoding GAG and POL.

[0190] 48. The transfection composition according to any one of embodiments 41 to 47, wherein the fourth vector comprises a polynucleotide encoding REV.

[0191] 49. The transfection composition according to any one of embodiments 41 to 48, wherein the CAR immunely and specifically targets B cell maturation antigen (BCMA).

[0192] 50. The transfection composition according to any one of embodiments 41 to 49, wherein the first carrier comprises SEQ ID NO: 1.

[0193] 51. The transfection composition according to any one of embodiments 41 to 50, wherein the second carrier comprises SEQ ID NO: 2.

[0194] 52. The transfection composition according to any one of embodiments 41 to 51, wherein the third carrier comprises SEQ ID NO: 3.

[0195] 53. The transfection composition according to any one of embodiments 41 to 52, wherein the fourth carrier comprises SEQ ID NO: 4.

[0196] 54. A method for manufacturing a BCMA CAR-T drug product, the method comprising:

[0197] Activated T cells were provided from apheresis material from subjects with multiple myeloma.

[0198] The T cells are brought into contact with lentivirus prepared by the method of any one of embodiments 1 to 40 or by using the transfection composition of any one of embodiments 41 to 53.

[0199] The transfected T cells were cultured to proliferate, and

[0200] Harvest the CAR-T drug product.

[0201] 55. The method according to embodiment 54, wherein the BCMA CAR-T drug product is cilta-cel.

[0202] 56. A BCMA CAR-T drug product, prepared by the method according to claim 54 or 55.

[0203] 57. A method for treating multiple myeloma, the method comprising administering the BCMA CAR-T drug according to claim 56 to a subject in need.

[0204] 58. A method for manufacturing a lentiviral vector for CAR-T cell therapy, the method comprising:

[0205] (a) Culture host cells in a bioreactor at a specified temperature and in a specified culture medium;

[0206] (b) Transfect the host cells with a transfection mixture, wherein the transfection mixture comprises a transfer vector containing the target gene (GOI) and one or more helper vectors selected from MD2g, MDLg and RSV-REV;

[0207] (c) Modify the ratio of the carrier in the transfection mixture, wherein the ratio of the carrier is adjusted to 11:3:1:5 (GOI:MD2g:MDLg) or 12:2:1:5;

[0208] (d) Harvest the lentiviral vector after a 24-hour incubation period following transfection.

[0209] 59. The method according to embodiment 58, wherein the host cell is HEK 293 cells cultured in a bioreactor with a working volume of 2L, 10L or 50L.

[0210] 60. The method according to embodiment 59 further includes the step of adding a shear protectant and an antifoaming agent to the bioreactor, wherein the shear protectant comprises a Kolliphor solution.

[0211] 61. A method for optimizing lentiviral vector yield in CAR-T manufacturing, comprising:

[0212] (a) Transfecting cultured host cells with a mixture of lentiviral vectors, said lentiviral vectors including GOI vector, MD2g, MDLg and RSV-REV;

[0213] (b) Adjusting the ratio of GOI vector to helper vector to optimize infectious titer, wherein the ratio of GOI:MD2g:MDLg is specified.

[0214] The ratio was adjusted to 11:3:1:5 or 12:2:1:5;

[0215] (c) Harvest the cells 24 hours after transfection to reduce impurities and optimize titer recovery.

[0216] 62. The method according to embodiment 61 further includes a purification process involving clarification, nuclease digestion, anion exchange purification, sterile filtration, and ultrafiltration / diafiltration (UF / DF).

[0217] 63. A method for improving impurity distribution in lentiviral vector production, the method comprising:

[0218] (a) Culturing HEK 293 cells in a bioreactor;

[0219] (b) Transfect the cells with a vector mixture containing GOI, MD2g, MDLg and RSV-REV vectors in a ratio of 11:3:1:5 or 12:2:1:5;

[0220] (c) Harvest the cells 24 hours after transfection to produce a lentiviral vector with reduced levels of p24, host cell protein (HCP), and host cell DNA (HC-DNA) compared to the lentiviral vector harvested 48 hours after transfection.

[0221] 64. The method according to implementation plan 63, wherein the harvested lentiviral vectors exhibit a 50% to 90% reduction in p24 levels compared to harvesting at 48 hours.

[0222] 65. A lentiviral vector produced by the method according to embodiment 64, wherein the vector has improved transduction efficiency, reduced impurity levels and enhanced quality properties, the lentiviral vector being used in CAR-T cell therapy.

[0223] 66. A method for scaling up lentiviral vector production to a 50L bioreactor, the method comprising:

[0224] (a) Upstream cell culture and transfection were performed in a 50L bioreactor;

[0225] (b) The cells were transfected with a vector mixture containing GOI, MD2g, MDLg and RSV-REV in a ratio of 11:3:1:5;

[0226] (c) Harvest the lentiviral vector 24 hours after transfection;

[0227] (d) subject the harvested material to downstream purification, including clarification, nuclease digestion, anion exchange purification and ultrafiltration / percolation.

[0228] 67. The method according to embodiment 66, wherein the infectious titer of the lentiviral vector produced on a 50L scale is equivalent to or higher than that produced on a smaller scale.

[0229] Example

[0230] Example 1: Modification of the carrier ratio for manufacturing CAR-T drug products

[0231] The manufacture of biopharmaceutical products, such as CAR-T cell therapy products, is a complex, multi-day process. A key step is providing lentiviruses to transduce enriched T cells for the production of CAR-T cell therapy products. Lentiviral manufacturing itself is a complex, multi-day process, typically divided into upstream and downstream processing. Upstream processing establishes production, while downstream processing harvests and prepares the lentiviruses. A general overview of the entire lentivirus manufacturing process is as follows: Figure 1 As depicted in the flowchart. Not wanting to be bound by theory, upstream processing can typically be divided into two stages: 1) pre-culture and amplification, which can take up to 22 days, and 2) bioreactor production, which can take up to 4 days.

[0232] Phase 1 began with thawing the host cell material (HEK 293 cells used here) and culturing it in 250 mL shake flasks for 4 days (passage 0). Cells were then cultured in 250 mL shake flasks for 3 days (passage 1); in 500 mL shake flasks for 4 days (passage 2); in 2 x 1 L shake flasks for 3 days (passage 3); in 20 L swirl bags for 4 days (passage 4); and in 50 L swirl bags for 4 days (passage 5).

[0233] In Phase 2, cells from passage 5 and beyond were cultured in a 50L bioreactor to produce lentiviruses. The 50L bioreactor was set up with culture medium and temperature controls one day prior to inoculation, and then on day 0, cells from passage 5 were inoculated into the 50L bioreactor. Immediately after inoculation, 10% Kolliphor solution was added as a shear protectant and antifoaming agent. Cells were cultured to day 2, where cell cultures were transfected with a transfection mixture containing a specific ratio of four different types of lentiviral vectors. Four hours after transfection, an anti-caking agent, transfection enhancer, and supplement were added to the bioreactor. Forty-eight hours post-transfection, the bioreactor was prepared for harvesting and clarification (Phase 3). Figure 1 And further downstream processing.

[0234] To determine whether harvest yield could be increased, modifications to the lentiviral vector ratio were examined. In lentiviral vector product systems, the natural viral genome is split into multiple helper vectors (typically four), which reduces the risk of generating a replicating virus. The transfer vector contains the target gene (GOI), specifically a CAR-coding sequence. Also present are an envelope vector encoding VSVG (“MD2g”), a first packaging vector encoding GAG and POL (“MDLg”), and a second packaging vector encoding REV (“RSV-REV”). A vector illustration of the GOI vector is shown in [image / image / description]. Figure 2A The vector illustration of the MD2g vector is shown in the figure. Figure 2B The vector illustration of the MDLg vector is shown in the figure. Figure 2C In the middle; and the vector illustration of the RSV-REV vector is shown in the figure. Figure 2D middle.

[0235] Typically, these vectors are present in the transfection mixture in a 2:1:1:1 ratio (GOI:MD2g:MDLg:RSV-REV). Alternative vector ratios were designed and tested using the following criteria: (1) a total vector amount constant; (2) the amount of the transfer vector encoding the CAR must be greater than or equal to 5; (3) the amount of all other vectors must be greater than or equal to 1; and (4) the amount of the transfer vector must be greater than the amount of any other vector.

[0236] Tables 1, 2, and 3 below list the carrier ratios for all tests. To facilitate testing, the study was divided into three blocks. Various conditions were distributed across each block to cover the entire range, so the data were expected to show the same trend in each block. The analysis was based on four quality attributes: 1) the infectious titer of SUPT1 (an indicator of infected / working particles); 2) the infectious titer according to the AD TU Flow method (an indicator of infected / working particles); 3) p24 (an indicator of total infectious and non-infectious particles); and (4) the P / I ratio (an indicator of total particles per infected / working particle).

[0237] Table 1: Tested Carrier Ratio Group 1

[0238] Block Operation number GOI MD2g MDLg RSV-REV 1 1 8 4 4 4 1 2 16 1 1 2 1 3 12 4 3 1 1 4 12 1 2 5 1 5 12 1 5 2 1 6 6 4 5 5 1 7 14 3 1 2 1 8 8 5 3 4 1 9 14 1 4 1 1 10 8 2 5 5 1 11 10 3 5 2 1 12 10 5 2 3 1 13 12 3 4 1 1 14 10 2 4 4 1 15 10 4 4 2 1 16 10 1 4 5 1 17 8 4 3 5 1 18 14 1 1 4

[0239] Table 2: Tested Carrier Ratio Group 2

[0240] Block Operation number GOI MD2g MDLg RSV-REV 2 21 8 4 4 4 2 22 10 5 3 2 2 23 8 4 5 3 2 24 8 5 4 3 2 25 12 5 1 2 2 26 16 1 2 1 2 27 10 1 5 4 2 28 12 4 1 3 2 29 10 4 1 5 2 30 10 4 5 1 2 31 14 2 1 3 2 32 12 2 1 5 2 33 6 5 4 5 2 34 14 3 2 1 2 35 12 1 3 4 2 36 14 1 2 3 2 37 12 2 5 1 2 38 10 2 5 3 2 39 8 3 4 5

[0241] Table 3: Tested Carrier Ratios (Group 3)

[0242] Block Operation number GOI MD2g MDLg RSV-REV 3 41 8 4 4 4 3 42 8 5 5 2 3 43 6 5 5 4 3 44 8 3 5 4 3 45 10 2 3 5 3 46 14 1 3 2 3 47 16 2 1 1 3 48 10 4 2 4 3 49 12 5 2 1 3 50 10 5 1 4 3 51 12 3 1 4 3 52 12 1 4 3 3 53 12 4 2 2 3 54 12 2 2 4 3 55 8 5 2 5 3 56 14 4 1 1 3 57 10 5 4 1 3 58 14 2 3 1 3 59 10 3 2 5 3 60 8 4 4 4

[0243] Both MDLg and RSV-REV vectors showed SUPT1 infectious titers in all blocks. Figure 3A ) and AD TUFlow infectious titer ( Figure 3B The results showed a consistent trend. In contrast, conflicting trends were observed for the GOI and MD2G vectors. Therefore, additional experiments were designed to investigate the levels of the GOI and MD2G vectors while maintaining the optimal levels of the MDLg and RSV-REV vectors.

[0244] Table 4 below lists the additional vector ratios tested. Except for the 8:4:4:4 control ratio in the first and last runs, MDLg and RSV-REV levels remained constant at 1 (MDLg) and 4 or 5 (RSV-REV). GOI levels varied from a low of 8 to a high of 14. MD2G levels varied from a low of 1 to a high of 5.

[0245] Table 4: Ratio of Additional Test Carriers

[0246] run GOI part MD2.G part MDLg section RSV-REV section 1 8 4 4 4 2 9 5 1 5 3 14 1 1 4 4 11 3 1 5 5 14 1 1 4 6 12 2 1 5 7 10 4 1 5 8 13 1 1 5 9 11 3 1 5 10 9 5 1 5 11 13 1 1 5 12 9 5 1 5 13 10 4 1 5 14 12 2 1 5 15 13 1 1 5 16 14 1 1 4 17 12 2 1 5 18 11 3 1 5 19 10 4 1 5 20 8 4 4 4

[0247] Again, based on the infectious titer (an indicator of infected / working particles) according to the SUPT1 method, Figure 4A ) and infectious titer (an indicator of infected / working particles) according to the AD TUFlow method. Figure 4B The analysis of these additional ratios was performed. The entire block of ratios listed in Table 4 was repeated twice. The results showed that the vector ratios 11:3:1:5 and 12:2:1:5 appeared to be the strongest candidates. To confirm their improvement over the standard 2:1:1:1 vector ratio, confirmatory test runs were performed. Three runs were run for each of the 2:1:1:1 control, 11:3:1:5, and 12:2:1:5 vector ratios, and both experimental ratios showed higher titers than the control ratio (e.g., ...). Figure 5A (as shown in the graphs of SUPT1 and xE6) and a lower ratio of infectious particles (e.g.) Figure 5B The figure for API P24 is shown.

[0248] Example 2: Modification of harvest time for manufacturing CAR-T drug products

[0249] like Figure 1 As shown, cells are typically harvested and prepared for further downstream processing 48 hours after transfection. Without being bound by theory, it is assumed that the transfection process triggers a certain amount of cell death in the culture, which can lead to increased culture impurities as dead cells rupture over time. Furthermore, lentiviruses have relatively short half-lives at cell culture temperatures, and the rate at which infectious particles lose infectivity after transfection may exceed the rate at which the cells generate an infectious titer. Therefore, there may be an optimal time during which the titer remains similar to or potentially higher than that recovered 48 hours post-transfection, but with potentially lower levels of impurities.

[0250] Therefore, use Figure 1 Experiments were conducted using a scaled-down model of the commercial 50L process described in [reference needed] to examine harvest time conditions. The standard HEK293F cell line and the standard 2:1:1:1 lentiviral vector ratio (GOI:MD2g:MDLg:RSV-REV, see Example 1) were used. Harvest times of 24 hours, 36 hours, 48 ​​hours (control), and 72 hours were employed. Harvest times of 24 hours and 36 hours produced similar infectious titers compared to the 48-hour control. Figure 6A However, the 24-hour harvest time is significantly superior to all other harvest times because of the lower levels of impurities: fewer physical particles are present at harvest. Figure 6B (Figure P24), host cell protein (HCP) decreased at harvest ( Figure 6C ), and the reduction of host cell DNA (HCDNA) at harvest ( Figure 6D ).

[0251] Example 3: Modification of carrier ratio and harvest time for manufacturing CAR-T drug products

[0252] Considering the results of alternative lentiviral vector ratios (Example 1) and shorter harvest times (Example 2), harvest data were collected at various scales (e.g., 2L and 10L bioreactors) with 24-hour harvest times at a 2:1:1:1 vector ratio (n=23), 24-hour harvest times at an 11:3:1:5 vector ratio (n=26), 48-hour harvest times at a 2:1:1:1 vector ratio (n=25), or 48-hour harvest times at an 11:3:1:5 vector ratio (n=19). The results showed that for both 24-hour harvest times (regardless of the ratio), the infectivity titer trend at harvest was slightly lower, while at 48 hours, the 11:3:1:5 vector ratio group exhibited the highest infectivity titer. Figure 7AHowever, purified data (not shown) indicated no significant decrease in titer during additional downstream steps. Nevertheless, testing revealed significantly lower impurity levels under 24-hour harvest conditions, with the 24-hour 11:3:1:5 carrier ratio group exhibiting the lowest infectivity particle ratio (infectivity particles, ...). Figure 7B HCDNA, Figure 7C HCP, Figure 7D ).

[0253] Based on these results, the complete end-to-end drug product run using lentiviruses manufactured by different methods was analyzed post-harvest and downstream processing, as well as at the final drug product stage. Cell cultures were used in 2L or 10L bioreactors, divided into three groups: lentiviruses manufactured at a vector ratio of 2:1:1:1 at a harvest time of 48 hours post-transfection (control), lentiviruses manufactured at a vector ratio of 2:1:1:1 at a harvest time of 24 hours post-transfection, and lentiviruses manufactured at a vector ratio of 11:3:1:5 at a harvest time of 24 hours post-transfection. This data was also compared to a 50L standard control. Post-harvest, downstream purification under all conditions involved clarification via a Sartopure PP3 deep-layer filter followed by a Sartopore 2XLG filter series, nuclease digestion to remove vector and host cell DNA, AEX membrane-based purification and aseptic filtration, and finally, hollow fiber ultrafiltration / percolation (UF / DF). The drug product was then concentrated and formulated.

[0254] The upstream results at harvest time are shown in Figures 8A to 8D The average infectious titer was relatively similar across all conditions. Figure 8A The 24-hour conditions again showed significantly lower levels of P24, HCP, and HCDNA impurities than the control (see [link to relevant documentation]). Figure 8B , Figure 8C and Figure 8D ).

[0255] Downstream results and formulations after downstream processing, such as Figures 9A to 9G As shown. Both 24-hour conditions showed similar infectious titers, only slightly lower than the complete 50L control. Figure 9A and Figure 9B Furthermore, it continues to exhibit significantly lower impurity levels:

[0256] • The 24-hour standard ratio condition showed a reduction of approximately 70% in p24 compared to the control, and the 24-hour 11:3:1:5 ratio condition showed a reduction of approximately 90% in p24 levels. Figure 9C )

[0257] • The 24-hour standard ratio condition showed a p / I ratio reduction to approximately 1 / 3.5 compared to the control, and the 24-hour 11:3:1:5 ratio condition showed a p / I level reduction to approximately 1 / 17. Figure 9D )

[0258] • HPC levels under both 24-hour conditions were less than half that of the control. Figure 9E )

[0259] • Compared with the control, the HCDNA levels under both 24-hour conditions decreased by more than one log. Figure 9F )

[0260] • Compared to the control, the vector DNA levels under both 24-hour conditions decreased by up to 70% ( Figure 9G )

[0261] • The 10L and 50L control conditions showed similar impurity levels. Figures 9C to 9G )

[0262] The final drug product results are shown in Figures 10A to 10D In both 24-hour conditions, higher transduction efficiency was observed compared to the standard control. Both 24-hour conditions showed a higher percentage of CAR T cells, with the highest level observed in the 24-hour 11:3:1:5 ratio condition. Figure 10A Drug activity, carrier copy number (VCN), and potency did not show significant differences between conditions (respectively, respectively). Figure 10B , Figure 10C and Figure 10D ).

[0263] To fully confirm the above results, two complete end-to-end drug product manufacturing runs were conducted, each starting with a single sample from one patient. However, each run did not consist of just one transduction and amplification, but rather four separate but simultaneous transduction and amplification runs, differing only in the method of lentivirus manufacturing: 1) 50L bioreactor, 48 hours post-transfection incubation, 2:1:1:1 vector ratio control group (50L control); 2) 10L bioreactor, 48 hours post-transfection incubation, 2:1:1:1 vector ratio control group (10L control); 3) 10L bioreactor, 24 hours post-transfection incubation, 2:1:1:1 vector ratio experimental group (10L option 1); and 4) 10L bioreactor, 24 hours post-transfection incubation, 11:3:1:5 vector ratio experimental group (10L option 2). A flowchart of a complete end-to-end run with the above four groups is shown below. Figure 11 middle.

[0264] At the end of each run, the final drug product is analyzed, and the results are presented. Figures 12A to 12E The data from the two runs are shown separately. The data show higher transduction efficiency in both 24-hour groups, with the 11:3:1:5 carrier ratio group showing the best performance in both runs. Figure 12A In the vitality of drug products ( Figure 12B ) and carrier integration (VCN, Figure 12C Regarding T-cell immunophenotypes, there were no significant differences among the groups. Furthermore, under all conditions, there were no significant differences in T-cell immunophenotypes. Figure 12D ) or cell growth ( Figure 12E There was no significant effect. Therefore, compared with the two control groups, both 24-hour groups showed a higher percentage of drug product without any impairment, with the 11:3:1:5 carrier ratio group showing the best performance.

[0265] Example 4: 50L scale in lentivirus manufacturing

[0266] The experiments conducted in Example 4 aimed to evaluate the performance and scalability of the lentiviral vector (LVV) manufacturing process at a 50L bioreactor scale. In lentiviral manufacturing, scaling up from smaller bioreactor volumes is crucial to meeting the production demands of CAR-T cell therapy. The manufacturing process, as previously described in Examples 1-3, involves multi-stage procedures initially tested and optimized at smaller scales (specifically, 2L and 10L bioreactors). Examples 1-3 demonstrated that modifications to the vector ratio and harvest time affect the quality and yield of LVV, thereby influencing the infectious titer and impurity levels of the final product.

[0267] Based on these findings, scaling up to a 50L bioreactor aimed to validate whether the improvements observed at smaller scale could be sustained or enhanced in larger production runs. Here, the effects of different harvest times (24 hours vs. 48 hours post-transfection) and vector ratios (2:1:1:1 vs. 11:3:1:5) on key parameters such as infectious titer, impurity levels, and overall LVV product quality were evaluated. The goal was to ensure the process remained robust and efficient at a 50L scale, thereby providing a reliable method for the large-scale production of lentiviral vectors for CAR-T cell therapy products.

[0268] Three different experimental conditions were evaluated in this study:

[0269] • Control: Tested at all three scales (2L, 10L and 50L) with a vector ratio of 2:1:1:1 and a harvest time of 48 hours post-transfection;

[0270] • Option 1: Test at all three scales (2L, 10L and 50L) while maintaining the same 2:1:1:1 vector ratio, harvest time 24 hours after transfection;

[0271] • Option 2: Evaluate only at 2L and 10L scales, with a modified 11:3:1:5 vector ratio and a harvest time of 24 hours post-transfection.

[0272] Following upstream bioreactor operation, the harvested material underwent downstream purification processes, such as... Figure 13 As described in the text, the initial steps involve clarification using a Sartopore PP3 depth filter, followed by clarification using a Sartopore 2XLG filter series to remove cell debris. Nuclease digestion is then performed to degrade residual plasmids and host cell DNA. The clarified and digested material is then subjected to purification and sterile filtration using an anion exchange (AEX) membrane to remove any remaining impurities. The final step involves ultrafiltration / diafiltration (UF / DF) using hollow fiber technology to concentrate the LVV and formulate it into the final pharmaceutical substance.

[0273] Both infectious titers and impurity levels present at harvest were assessed. This involved sampling from the bioreactor at a specified harvest time, followed by analytical determination to quantify infectious titers and impurity levels. These assessments provide an overview of the upstream harvested material. Three experimental conditions were evaluated, and upstream results at harvest are shown below. Figures 14A to 14D These figures present specific results from the 50L control condition and the 50L Option 1 condition. AD IT flow cytometry indicates that, when operated under control conditions, the 50L bioreactor produces slightly higher titers than the smaller-scale and Option 1 bioreactors. Figure 14A Compared to each control, the p24 level was reduced in option 1, option 2, and the 50L option 1 condition (). Figure 14B HCP and HC-DNA results showed low impurity levels even at a 50L scale under 24-hour harvest conditions. Figures 14C to 14D These results indicate that even at a carrier ratio of 11:3:1:5 and a scale of 50L, shorter harvest times effectively reduce impurity levels without compromising infectious titers.

[0274] The downstream final drug substance LVV infectivity titer was analyzed to assess the impact of different process conditions and bioreactor size on the yield of infectious particles. The yield of IT-FLOW (IT-FLOW) was compared in 2L, 10L, and 50L bioreactor sizes. Figure 15A ) and IT-PCR ( Figure 15B The infectious titers were measured, with particular attention paid to results obtained from a 50L bioreactor. Experimental conditions were similar to those in the upstream harvest experiment, where the control and Option 1 conditions were tested at all three scales, while Option 2 was tested only at 2L and 10L scales. Options 1 and 2 produced similar infectious titers ( Figure 15AThis indicates that the reduced harvest time does not adversely affect infection yield. Compared to smaller scale, the 50L bioreactor operation showed a slightly higher IT-FLOW titer ( Figure 15A This indicates that the process effectively scales up to larger volumes. Furthermore, the 50L Option 1 condition, with a 24-hour harvest time and a 2:1:1:1 carrier ratio, produced infectious titers comparable to the control, but with the added benefit of a shorter production time. Figure 15A Overall, the data indicate that scaling up to a 50L bioreactor does not compromise infectious titers, with the 24-hour harvest time (Option 1) showing consistency across all test scales. Maintaining or improving infectious titers at the 50L scale highlights the potential for large-scale LVV production.

[0275] Downstream analysis of the final LVV products also includes the p24 level ( Figure 15C ) and the ratio of physical titer to infectious titer (P / I) Figure 15D The p24 protein is a component of the viral capsid and serves as a marker of the total number of viral particles. The p / I ratio provides insight into the proportion of functional (infectious) viral particles relative to the total number of particles, thus providing a measure of the efficiency and quality of the LVV production process.

[0276] Using the same experimental conditions as previously described, p24 levels and P / I ratios were compared at different bioreactor sizes (2L, 10L, and 50L) and under different process conditions. Figure 15C As shown, p24 levels were reduced in Options 1 (approximately 50% reduction) and Options 2 (approximately 87% reduction) compared to the control. This reduction was consistent across different scales, with the 50L bioreactor under Option 1 conditions exhibiting a lower p24 level compared to the 50L bioreactor under control conditions. The reduced p24 level indicates the presence of fewer non-infectious particles, suggesting a higher quality carrier formulation. Figure 15D The P / I ratio data presented show a similar trend. The P / I ratios for Options 1 and 2 are lower than the control P / I ratio, further demonstrating the improved quality of LVV produced under these conditions. The 50L bioreactor under Option 1 conditions exhibits a P / I ratio comparable to that observed at smaller scales, indicating that process scaling up does not adversely affect the ratio of infectious to non-infectious particles. In summary, both Options 1 and 2 demonstrate improvements over the control conditions, with these benefits maintained across different bioreactor scales, including the 50L scale. This suggests that these optimized conditions are robust and scalable.

[0277] Downstream analysis of the final LVV product also includes the assessment of impurity levels, specifically, host cell proteins (HCPs). Figure 15E ), plasmid DNA (pDNA) Figure 15F ) and host cell DNA (HC-DNA) Figure 15G Apply the same experimental conditions as previously described. Figure 15E As shown, HCP levels were reduced in both Options 1 and 2 compared to the control. This reduction was consistent across all scales, with the 50L bioreactor under Option 1 conditions exhibiting a significant reduction in HCP levels compared to the 50L control. Figure 15F The HC-DNA levels in the final LVV products were depicted, showing a reduction of more than one log compared to controls (including the Option 1 50L group). This significant reduction highlights the effectiveness of the 24-hour harvest time in minimizing the presence of host cell genetic material. pDNA levels were also significantly reduced under the 24-hour harvest condition. Figure 15G Compared to the control, both Option 1 and Option 2 showed reduced pDNA levels, with Option 1 in the 50L bioreactor again exhibiting particularly low plasmid DNA levels. Overall, the data highlight the improvement in impurity levels achieved by optimizing the 24-hour harvest conditions. At all scales, and particularly in the 50L bioreactor, the reductions in HC-DNA, plasmid DNA, and HCP indicate that these conditions not only maintain high product yield and quality but also improve the purity of the final LVV product.

[0278] Next, transduction efficiency, viability, vector copy number, and potency were analyzed under different conditions at a 50L scale. CAR-T cell transduction efficiency was assessed based on the percentage of CAR-positive cells. The control group (involving 48-hour post-transfection harvest time and a 2:1:1:1 vector ratio) was compared with Option 1 (involving 24-hour post-transfection harvest time and the same vector ratio but performed at two different MOI levels of 0.5 and 0.25). Figure 16A and Figure 17A As shown, the 50L scale run in Option 1 demonstrated approximately a two-fold increase in transduction efficiency at MOIs of 0.5 and 0.25, indicating a significant improvement relative to the control. Additionally, patient-specific changes were observed, such as... Figure 17A As shown, the percentage of CAR-positive cells varies among individual patients.

[0279] Assess the activity of the CAR-T drug product to determine its impact on the 24-hour harvest time at a 50L scale compared to a 48-hour control (Option 1). Figure 16B and Figure 17BAs shown, no significant difference in DP viability was observed between the control and Option 1 conditions. The data indicate that shortening the harvest time to 24 hours does not adversely affect cell viability, as high levels of viability remained consistent with the control conditions. This consistency in MOI levels across different Option 1 conditions further supports the feasibility of the improved process without compromising product quality.

[0280] The vector copy number of each transduced cell was also evaluated under control and option 1 conditions. Figure 16C and Figure 17C The results presented showed no significant difference in VCN between the control and Option 1 conditions at various scales. This indicates that the 24-hour harvest time and the different MOI levels in Option 1 do not impair the genetic integrity of CAR-T cells. The potency of the CAR-T drug product, measured by IFN-γ levels, was also analyzed to assess the impact of the modified process conditions. Figure 16D and Figure 17D The study showed no observable effect on CAR-T cell efficacy between the control and Option 1 groups. The consistency of IFN-γ levels under different conditions further supports the efficacy at 24-hour harvest time across both MOI levels.

[0281] The findings from the 50L scale demonstrate the feasibility and potential advantages of implementing a 24-hour harvest time in conjunction with modified vector ratios in the production of CAR-T cell therapy products. The 24-hour harvest time, particularly when combined with an optimized vector ratio of 2:1:1:1 at different MOI levels, consistently yielded comparable or superior results in transduction efficiency, viability, vector copy number, and potency. These results indicate that the process modifications did not compromise product quality and, in some cases, even enhanced key quality attributes. Overall, the successful application of these improved conditions at the 50L scale supports their scalability and robustness.

Claims

1. A method for preparing lentivirus, the method comprising: Transfecting host cells with a transfection composition, wherein the transfection composition comprises: The first vector containing a polynucleotide encoding CAR The second, third, and fourth carriers, and Transfection medium; The ratio of the first carrier to the second carrier to the third carrier to the fourth carrier is 2:1:1:1, 11:3:1:5, or 12:2:1:

5. Culture the transfected host cells to proliferate, and Harvest the lentivirus, wherein the harvest occurs approximately 24 hours after transfection.

2. A method for preparing lentivirus, the method comprising: Transfecting host cells with a transfection composition, wherein the transfection composition comprises: The first vector containing a polynucleotide encoding CAR The second, third, and fourth carriers, and Transfection medium; The ratio of the first carrier to the second carrier to the third carrier to the fourth carrier is 11:3:1:5 or 12:2:1:

5. Culture the transfected host cells to proliferate, and Harvest the lentivirus, wherein the harvest occurs less than or equal to about 48 hours after transfection.

3. The method according to claim 1, wherein the ratio is 2:1:1:

1.

4. The method according to claim 1 or 2, wherein the ratio is 11:3:1:

5.

5. The method according to claim 1 or 2, wherein the ratio is 12:2:1:

5.

6. The method according to any one of claims 3 to 5, wherein the harvest occurs approximately 24 hours after transfection.

7. The method according to any one of claims 1 to 6, wherein the first vector, the second vector, the third vector and the fourth vector comprise lentiviral vectors.

8. The method of claim 1, wherein the ratio is 2:1:1:1, and the harvest occurs approximately 24 hours after transfection.

9. The method of claim 1, wherein the ratio is 11:3:1:5, and the harvest occurs approximately 24 hours after transfection.

10. The method of claim 1, wherein the ratio is 12:2:1:5, and the harvest occurs approximately 24 hours after transfection.

11. The method according to any one of claims 1 to 10, wherein the second vector comprises a polynucleotide encoding a lentiviral envelope protein.

12. The method of claim 11, wherein the lentiviral envelope protein is vesicular stomatitis virus G (VSVG).

13. The method according to any one of claims 1 to 12, wherein the third vector comprises polynucleotides encoding GAG and POL.

14. The method according to any one of claims 1 to 13, wherein the fourth vector comprises a polynucleotide encoding REV.

15. The method according to any one of claims 1 to 14, wherein the culture takes place in a bioreactor.

16. The method of claim 15, wherein the bioreactor is a 2L, 10L, or 50L bioreactor.

17. The method according to claims 1 to 16, wherein the host cell is a HEK 293 cell.

18. The method according to any one of claims 1 to 17, wherein the CAR immune-specifically targets B cell maturation antigen (BCMA).

19. A method for preparing a lentivirus, the method comprising: Transfecting host cells with a transfection composition, wherein the transfection composition comprises: A first vector, comprising a polynucleotide encoding a CAR that specifically targets BCMA. The second, third, and fourth carriers, and Transfection medium; The ratio of the first carrier to the second carrier to the third carrier to the fourth carrier is 2:1:1:1, 11:3:1:5, or 12:2:1:

5. Culture the transfected host cells to proliferate, and Harvest the lentivirus, wherein the harvest occurs approximately 24 hours after transfection.

20. A method for preparing a lentivirus, the method comprising: Transfecting host cells with a transfection composition, wherein the transfection composition comprises: A first vector, comprising a polynucleotide encoding a CAR that specifically targets BCMA. The second, third, and fourth carriers, and Transfection medium; The ratio of the first carrier to the second carrier to the third carrier to the fourth carrier is 11:3:1:5 or 12:2:1:

5. Culture the transfected host cells to proliferate, and Harvest the lentivirus, wherein the harvest occurs less than or equal to about 48 hours after transfection.

21. The method of claim 19, wherein the ratio is 2:1:1:

1.

22. The method according to claim 19 or 20, wherein the ratio is 11:3:1:

5.

23. The method according to claim 19 or 20, wherein the ratio is 12:2:1:

5.

24. The method according to any one of claims 20 to 23, wherein the harvest occurs about 24 hours after transfection.

25. The method according to any one of claims 19 to 24, wherein the first vector, the second vector, the third vector, and the fourth vector comprise a lentiviral vector.

26. The method of claim 19, wherein the ratio is 2:1:1:1, and the harvest occurs approximately 24 hours after transfection.

27. The method of claim 19, wherein the ratio is 11:3:1:5, and the harvest occurs approximately 24 hours after transfection.

28. The method of claim 19, wherein the ratio is 12:2:1:5, and the harvest occurs approximately 24 hours after transfection.

29. The method according to any one of claims 19 to 28, wherein the second vector comprises a polynucleotide encoding a lentiviral envelope protein.

30. The method of claim 29, wherein the lentiviral envelope protein is vesicular stomatitis virus G (VSVG).

31. The method according to any one of claims 19 to 30, wherein the third vector comprises polynucleotides encoding GAG and POL.

32. The method according to any one of claims 19 to 31, wherein the fourth vector comprises a polynucleotide encoding REV.

33. The method according to any one of claims 19 to 32, wherein the culture takes place in a bioreactor.

34. The method of claim 33, wherein the bioreactor is a 2L, 10L, or 50L bioreactor.

35. The method according to any one of claims 19 to 34, wherein the host cell is a HEK 293 cell.

36. The method according to any one of claims 19 to 35, wherein the first carrier comprises SEQ ID NO:

1.

37. The method according to any one of claims 19 to 36, wherein the second carrier comprises SEQ ID NO:

2.

38. The method according to any one of claims 19 to 37, wherein the third carrier comprises SEQ ID NO:

3.

39. The method according to any one of claims 19 to 38, wherein the fourth carrier comprises SEQ ID NO:

4.

40. The method according to any one of claims 19 to 39, wherein the CAR-T drug product is cilta-cel.

41. A transfection composition comprising: The first vector containing a polynucleotide encoding CAR The second, third, and fourth carriers, and Transfection medium; The ratio of the first carrier to the second carrier to the third carrier to the fourth carrier is 2:1:1:1, 11:3:1:5, or 12:2:1:

5.

42. The transfection composition according to claim 41, wherein the ratio is 2:1:1:

1.

43. The transfection composition according to claim 41, wherein the ratio is 11:3:1:

5.

44. The transfection composition according to claim 14, wherein the ratio is 12:2:1:

5.

45. The transfection composition according to any one of claims 41 to 44, wherein the second vector comprises a polynucleotide encoding a lentiviral envelope protein.

46. ​​The transfection composition according to claim 45, wherein the lentiviral envelope protein is vesicular stomatitis virus G (VSVG).

47. The transfection composition according to any one of claims 41 to 46, wherein the third vector comprises a polynucleotide encoding GAG and POL.

48. The transfection composition according to any one of claims 41 to 47, wherein the fourth vector comprises a polynucleotide encoding REV.

49. The transfection composition according to any one of claims 41 to 48, wherein the CAR immunely and specifically targets B cell maturation antigen (BCMA).

50. The transfection composition according to any one of claims 41 to 49, wherein the first carrier comprises SEQ ID NO:

1.

51. The transfection composition according to any one of claims 41 to 50, wherein the second carrier comprises SEQ ID NO:

2.

52. The transfection composition according to any one of claims 41 to 51, wherein the third carrier comprises SEQ ID NO:

3.

53. The transfection composition according to any one of claims 41 to 52, wherein the fourth carrier comprises SEQ ID NO: 4.

Citation Information

Patent Citations

  • Chimeric antigen receptors based on single domain antibodies and methods of use thereof

    US10934363B2

  • Chimeric antigen receptors targeting BCMA and methods of use thereof

    US11535677B2

  • Improved t cell manufacturing process

    US20220017862A1

  • Manufacturing Anti-BCMA car t cells

    US20220195060A1

  • Windmill

    US353363A